This webinar will focus on how to develop innovative pharmacy education curricula to better respond to global public health needs. It will also discuss the importance of covering all pharmacy fields and specialties in the pharmacy program, and how to integrate digital health in the global pharmacy education to continuously enhance the quality of education and competencies of the pharmaceutical workforce, as having competent pharmaceutical workforce is critical to providing quality health care services

1. Highlight the importance of quality of education for pharmaceutical workforce to provide high quality health services
2. Understand the innovative pharmacy education curricula
3. Providing effective strategies for comprehensive pharmacy education and training
4. Examining global tools and approaches to integrate e-learning and digital health to enhance the quality of pharmacy education and competencies of health

Moderators:
- Hanane Kebaili, President of the Algerian Early Career Pharmacists Group , Fédération Algérienne de Pharmacie, Algeria
- Abby A. kahaleh, PhD, MS, BPharm, MPH, FAACP, Board of Trustees Faculty & Tenured Faculty of Clinical and Administrative Sciences, RUCSHP, USA

Panellists:
- Abeer Al-Ghananeem, Professor of Pharmaceutics and Biopharmaceutics, Associate Dean for Research College of Pharmacy and Health Sciences, Sullivan University, Louisville, Kentucky, USA
- Anisha Sandhu, FIP AcPS Communication & Collaboration Working Group Member, FIP Technology Forum Committee Member; Assistant Lecturer, Monash University Malaysia School of Pharmacy, Malaysia
- Martin Henman, Associate Professor in the Practice of Pharmacy, The School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Ireland
- Carl Schneider, Associate Professor in Pharmacy Practice, The University of Sydney School of Pharmacy, Faculty of Medicine and Health, Australia

Research has shown that women may receive less intensive, less effective and lower quality treatment due to stereotyped responses attributed to women, such as dramatising, overemphasising their experiences of pain, being more willing to report pain, inaccurately reporting pain or being less tolerant to pain than men. It results in the underestimation and undertreatment of women’s pain worldwide. This is often referred to as the “gender pain gap”.

Regarding the gender pain gap, self-awareness and training are not issues owned only by pharmacists; they should be shared with all healthcare professionals and the public.

Pharmacists can be supported to address the gender pain gap through education and partnerships. Good understanding of the variety of pain symptoms can support unbiased pain management. Pharmacists also have a responsibility to educate the public on where and how to seek help for pain management, thus further addressing the gender pain gap.

The event aims to

• Define the gender pain gap
• Increase awareness about gender pain gap
• Describe how pharmacists can be supported to address the issue
• Describe the knowledge and training for pharmacists to close the gender pain gap

Learning objectives:

• Understand the gender inequalities in pain research
• Increase their awareness of gender gap in treatment offers for pain management
• Describe knowledge and training status on unconscious bias towards women in pain management
• Define knowledge, attitudes and practices that pharmacists have, to close the gender pain gap
• Describe how pharmacists can be supported with e.g. training, tools to address gender inequalities in pain management, bring close the gender pain gap, achieve behavioural change towards women

Chair:
- Parisa Aslani, Professor, The University of Sydney School of Pharmacy, Australia

Facilitator:
- Aysu Selcuk, FIP Education and Primary Health Care Policies Specialist, The Netherlands

Panellists:
- Catherine Duggan, FIP CEO, The Netherlands
- Jonathan Penm, Senior lecturer, The University of Sydney School of Pharmacy, Australia
- Jack Collins, Postdoctoral Research Associate, The University of Sydney, Australia
- Leticia Caligaris, Community pharmacist lead, Executive committee member, member of Pharmacist Association of Uruguay
- Miranda Sertic, Associate Professor, Faculty of Pharmacy and Biochemistry, University of Zagreb, Croatia
- Roger Knaggs, Associate Professor in Clinical Pharmacy Practice, University of Nottingham, UK

Pharmacists have an important role in supporting the management of minor ailments in the community and promoting informed and responsible self-care. Gastroesophageal reflux is a common reason for consultations to community pharmacists, and symptoms associated with reflux can often be managed through non-prescription medicines. Pharmacists can assess and provide advice on both the pharmacological and non-pharmacological options that patients might follow, check for possible interactions with medication that patients might be taking, and provide education for improved self-care.

Attendees will learn about:

1. The resources FIP developed on reflux management
2. Understand the main therapeutic options to support relief of reflux-like symptoms
3. Explore pharmacists’ perspectives of reflux management

Moderator:
- Luís Lourenço, FIP Professional Secretary FIP, Portugal

Panellists:
- Rúben Viegas, Practice Development and Transformation, Projects Coordinator FIP, The Netherlands
- Kai Zhen Yap, Lecturer, National University of Singapore, Department of Pharmacy, Singapore
- Ana Zovko, Member of the ExCo of CPS of the FIP, Owner and director , Pharmacy institution Afarm, Bosnia and Herzegovina
- Pali Hungin, Emeritus professor, Institute of Health and Society, Faculty of Medical Sciences, Newcastle University, UK
- Peter Kahrilas, Professor of medicine,, Northwestern University, Feinberg School of Medicine, USA

The COVID-19 pandemic highlighted the requirement for current and future pharmacy education to be improved to strengthen the pharmacy profession and improve resilience. With the demand and options at higher education increasing, enrolment strategies have become more critical to pharmacy institutions.

FIP AIM has developed a handbook to support academic pharmacy leaders to update enrolment management strategies in schools of pharmacy. The webinar will officially launch the handbook and go through the background of the handbook development and how it can help global health leaders to implement new enrolment methods.

• Develop strategies to recruit more and better students into pharmacy schools using traditional and social media
• Advocate for the profession, its scope of practice, and its importance in the healthcare system
• Reflect on a global integrated approach to foster student interest and improve admissions

Moderator:
- Pierre Moreau, Dean FIP, Kuwait University, Kuwait

Facilitator:
- Ozge Ozer, FIP Educational Partnership Manager, Turkey

Panellists:
- Lilian Azzopardi, FIP AIM Chair-elect & AIM Advisory Committee member, Head, Department of Pharmacy University of Malta-Malta
- Brian Hemstreet, Associate Dean for Student Affairs University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences-USA
- Frank Moriarty, Pharmacist and senior research fellow RCSI School of Pharmacy and Biomolecular Sciences-Ireland
- Gea Abigail U. Ecoy, Assistant Professor and Chair University of San Carlos-Philippines
- Hanan Refaat, Dean Future University-Egypt
- Marlon Prince, FIP AIM member, Director of Admissions at Howard University College of Pharmacy-USA
- Mohd Zulkefeli Mat Jusoh, FIP AIM member, Dean International Medical University-Malaysia
- Rajani Shakya, Head of Department of Pharmacy Kathmandu University-Nepal
- Wendy Cox,Assoc. Dean, Admissions and Accreditation, University of North Carolina at Chapel Hill Eshelman School of Pharmacy-USA

FIP is committed to supporting countries to develop policies that enable pharmacies and pharmacists to deliver integrated vaccination services throughout the life-course and as part of wider national immunisation policies. This event is delivered as part of a new FIP programme supported by Pfizer, which aims to provide our members with approaches and tools for tackling key policy enablers that determine equity, access and sustainability of pharmacy-based life-course immunisation.

Regulations of pharmacy practice is a critical determinant of pharmacists’ authority to administer and/or prescribe vaccines. FIP data shows that regulations on pharmacy-based vaccination vary widely across countries and regions. Understanding the different models and country experiences is key to wider implementation. This event will feature a number of pharmacy leadership bodies describing how pharmacy-based vaccination, including prescribing, is regulated in their countries.

Moderator:
- Jaime Acosta, FIP-CPS Professional Secretary Community, Pharmacist Farmacia Acosta, Spain

Panellists:
- Hanne Andresen, Director Pharmaceutical Affairs Norwegian Pharmacy Association, Norway
- Fei Sim, National President Pharmaceutical Society of Australia, Australia
- Luna Bizri, Founder and manager of community pharmacy; Clinical Assistant professor; Adjunct faculty member Lunapharm pharmacy; Lebanese International University; Lebanese American University, Lebanon
- Joyce Mariama Kallon, Team Lead for the supply Chain and logistics vaccine unit Immunisation unit, Sierra Leone

Telepharmacy has gained increasing importance in the delivery of pharmaceutical care, largely due to the COVID-19 pandemic which has placed enormous pressures on healthcare systems globally. There are some innovative models of telepharmacy services aimed at optimizing and improving access to pharmaceutical care, resulting in improved patient safety and outcomes. However, despite these benefits, major barriers for implementation of telepharmacy remain such as patient confidentiality and privacy of health information.

Attendees will learn about:

1. The global role of telehealth in supporting primary health care services
2. The current trends in telepharmacy around the globe
3. Examples of good practice in telepharmacy

Moderator:
- Lars-Åke Söderlund, FIP Vice President International Pharmaceutical Federation, Sweden

Panellists:
- Rúben Viegas, Practice Development and Transformation Projects Coordinator, The Netherlands
- Sarah Dineen-Griffin, FIP CPS ExCo member, Australia
- Jaime Acosta, Community pharmacist Farmacia Acosta, Spain
- Josep M. Guiu-Segura, Vice-president Euro, Hospital Pharmacy Section, International Pharmaceutical Federation, Director of Pharmacy and Medicines, Consortium of Health and Social Care of Catalonia, Spain
- Derrick Muneene, Unit Head, Digital Health Capacity Building and Collaboration, WHO, Switzerland 

Biorelevant in vitro performance testing of orally administered dosage forms has become an important tool for the assessment of drug product in vivo behavior. An in vitro performance test which mimics the intraluminal performance of an oral dosage form is termed biorelevant. Biorelevant tests have been utilized to decrease the number of in vivo studies required during the drug development process and to mitigate the risk related to in vivo bioequivalence studies.

Prediction of intraluminal performance of an orally administered dosage form and the active pharmaceutical ingredient with biorelevant in vitro performance testing requires appropriate simulation of luminal conditions. Key luminal parameters to be simulated may vary with the process to be simulated, the structure of the active pharmaceutical ingredient and the type of dosage form. A variety of biorelevant media have been proposed, making it now possible to simulate most regions in the gastrointestinal tract in both prandial states. The levels of biorelevance and accompanying decision tree may serve as a useful tool during formulation development, in order to ensure high quality, predictive performance results without unnecessary complexity of media.

• Participants will be introduced in biorelevant dissolution testing
• Participants will be informed on dissolution media that simulates the physicochemical characteristics of the contents of the gastrointestinal lumen
• Participants will be informed on the in vitro methodologies that have been shown to be useful in simulating the intraluminal environment

Chair:
- Horst-Dieter Friedel, FIP Chair Regulatory Sciences and Quality, Director Former at Bayer AG, Germany

Moderator:
- Christos Reppas, Professor in Pharmaceutics National and Kapodistrian University of Athens, Greece

Guests:
- Maria Vertzoni, Associate Professor in Pharmaceutical Technology and Biopharmaceutics National and Kapodistrian University of Athens, Greece

One year after the launch of the FIP global call to action on advancing pharmaceutical education, FIP will report on each region’s progress against the call to action, building on the results of the FIP-UNITWIN inter-regional impact workshops held in November 2022. The event will also host the launch of the FIP Education transformation toolkit, which will be a collection of FIP’s relevant publications and digital events to implement the FIP global call to action on advancing pharmaceutical education.

Objectives:
1. Present progress since 2021 on priority FIP Development Goals of the regions in the context of pharmaceutical education
2. Present progress on FIP-UNITWIN regional roadmaps 2021 and the impact on FIP global call to action on pharmaceutical education
3. Discuss the way forward for the delivery of each regions’ roadmaps with establishment of regional FIP-UNITWIN centres for excellence programme in the months ahead
4. Launch the FIP Education transformation toolkit

Moderators:
- Ralph J. Altiere, FIPEd Chair FIP and University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences- USA
- Lilian Azzopardi, FIP AIM Chair-elect , University of Malta -Malta

Guests:
- Dominique Jordan, FIP President, Switzerland
- Catherine Duggan, FIP CEO, UK

Panellists:
- Toyin Tofade, President Albany College of Pharmacy and Health Sciences, USA
- Silvana Nair Leite, Professor Federal University of Santa Catarina, Brazil
- Arinola Joda, Assistant Secretary & Editor-in- Chief, African Pharmaceutical Forum, Faculty of Pharmacy, University of Lagos, Nigeria
- Rajani Shakya, Ass.Prof. Department of Pharmacy, Kathmandu University, Nepal
- Mohamad Rahal, Dean School of Pharmacy, Lebanese International University, Lebanon
- Paul Gallagher, Prof.Department of Pharmacy, National University of Singapore, Singapure
- Nilhan Uzman, FIP Lead for Education & Primary Health Policies, Turkey
- Alison Etukakpan, Educational Partnership Specialist International Pharmaceutical Federation, Nigeria

Pharmacists as athlete support personnel have rooted themselves as key players in medical teams serving athletes. Sports pharmacy evolved from a niche practice during the establishment of WADA two decades ago, gaining traction with the publication of the FIP guidelines “The Role of the Pharmacist in the Fight against Doping in Sport” in 2014. Today, we recognise sports pharmacy as a specialty practice, fundamental to the antidoping movement and athlete health. Pharmacists provide accurate sports drug information, avoid inadvertent doping, and coordinate pharmacy services at sporting events. We present two successful models in education and proper training of pharmacists to work with athletes.

Attendees will learn about:

1. Exploring the specialty of sports pharmacy based on expert consensus
2. Discussing a foundation for sports pharmacy curricula
3. Describing a successful example of sports pharmacy practice

Moderator:
- Daragh Connolly, Chair Board of Pharmaceutical Practice, Ireland

Panellists:
- Ashley Anderson, Clinical Sports Pharmacy Specialist / Antidoping Pharmacist International Sports Pharmacists Network, USA
- David Mottram, Emeritus Professor- Liverpool John Moores University, UK
- Mark Stuart, Pharmacist to the International Olympic Committee Medical Commission International Olympic Committee, UK
- Claire May, Academic University of Brighton, UK
- Somer Helvaci, Lecturer IOC accredited sports pharmacist, Turkey
- Shigeo Yamamura, Specially-Appointed Professor Josai International University, Japan

Often, the most vulnerable population groups experience severe or even lethal forms of vaccine-preventable diseases, as well as losses in quality of life, functional ability and productivity. It is essential to identify these groups and their specific vaccination needs, and to take measures to improve vaccine confidence and uptake among them. Pharmacists play a key role in raising awareness and building confidence in vaccines, and in promoting a convenient access to vaccinations. Over several months, FIP organised a series of events focusing on the vaccination needs of several special-risk population groups. With this final event, we invite you to engage with an intersectoral roundtable on this topic and witness the launch of a summary publication and a series of short videos to support pharmacists in these roles.

By the end of the session participants will:
- Understand the specific vaccination needs of several special-risk population groups
- Become familiar with FIP’s resources on vaccination for special-risk groups
- Discuss the role of pharmacists in promoting vaccination uptake among different special-risk groups

Moderator:
- Catherine Duggan, FIP Chief Executive Officer, UK/Netherlands

Panellists:
- Jean-Luc Eiselé, CEO World Heart Federation, Switzerland
- Siân Williams, Chief Executive Officer International Primary Care Respiratory Group (IPCRG), Scotland (working internationally)
- Iryna Vlasenko, Vice president- International Diabetes Federation-Ukraine
- Howard Catton, Chief Executive Officer, International Council of Nurses, Switzerland/ United Kingdom
- Jane Barratt, Secretary-General International Federation on Ageing, Canada
- Rúben Viegas, FIP Practice Development and Transformation Projects Coordinator, Portugal
- Mary Ann Lumsden, FIGO Chief Executive, International Federation of Gynecology and Obstetrics (FIGO), UK

Often, the most vulnerable population groups experience severe or even lethal forms of vaccine-preventable diseases, as well as losses in quality of life, functional ability and productivity. It is essential to identify these groups and their specific vaccination needs, and to take measures to improve vaccine confidence and uptake among them. Pharmacists play a key role in raising awareness and building confidence in vaccines, and in promoting a convenient access to vaccinations. Over several months, FIP organised a series of events focusing on the vaccination needs of several special-risk population groups. With this final event, we invite you to engage with an intersectoral roundtable on this topic and witness the launch of a summary publication and a series of short videos to support pharmacists in these roles.

By the end of the session participants will:
- Understand the specific vaccination needs of several special-risk population groups
- Become familiar with FIP’s resources on vaccination for special-risk groups
- Discuss the role of pharmacists in promoting vaccination uptake among different special-risk groups

Moderator:
- Catherine Duggan, FIP Chief Executive Officer, UK/Netherlands

Panellists:
- Jean-Luc Eiselé, CEO World Heart Federation, Switzerland
- Siân Williams, Chief Executive Officer International Primary Care Respiratory Group (IPCRG), Scotland (working internationally)
- Iryna Vlasenko, Vice president- International Diabetes Federation-Ukraine
- Howard Catton, Chief Executive Officer, International Council of Nurses, Switzerland/ United Kingdom
- Jane Barratt, Secretary-General International Federation on Ageing, Canada
- Rúben Viegas, FIP Practice Development and Transformation Projects Coordinator, Portugal
- Mary Ann Lumsden, FIGO Chief Executive, International Federation of Gynecology and Obstetrics (FIGO), UK

Remuneration of pharmacy vaccinations is one of the key policy enablers of pharmacy-based vaccinations, and thus life-course immunisation. FIP data shows that remuneration models vary widely across countries and regions. Understanding the different models and country experiences is key to wider implementation. This event will feature a number of pharmacy leadership bodies sharing their remuneration models and journeys for the benefit of policy-enablement everywhere.

This event is delivered as part of a new FIP programme supported by Pfizer, which aims to provide our members with approaches and tools for tackling key policy enablers that determine equity, access and sustainability of pharmacy-based life-course immunisation.

Moderator:
- Sari Westermarck, Community pharmacist FIP Community Pharmacy Section, Finland

Panellists:
- Eleftherios Marinos, General Secretary-Federation of Pharmacists’ Cooperatives of Greece, Greece
- Ahmad Al-Rusasi, General manager/Lecturer Alnoor Drug Store, Jordan
- Sham Moodley, Pharmacist Pharmaceutical Society of South Africa/Independent Community Pharmacy Assoc (ICPA), South Africa
- Susan O’Dwyer, Head of Governance and Pharmacy Service, Irish Pharmacy Union, Ireland
- Luís Lourenço, President of the South and Autonomous Regions Branch of the Portuguese Pharmaceutical Society, Portuguese Pharmaceutical Society, Portugal

The COVID-19 pandemic is one of the greatest public health emergencies of our time. The development of new diagnostics, treatments and vaccinations has arguably required greater innovation and collaboration across research, pharmaceutical industry and healthcare sectors than ever before. This event reflects on innovations and collaborations during the COVID-19 pandemic. Consideration will be given to applying what has been learnt to future pandemics.

Aim
To reflect on innovations and collaborations in pharmaceutical science that have made an impact against COVID-19. To consider how to apply this learning to our response to future pandemics.

Learning objectives:

• Explain how pharmaceutical scientists innovated and collaborated in the fight against COVID-19.
• List challenges and opportunities for the development of diagnostics, treatments and vaccinations during the COVID-19 pandemic;
• Discuss approaches for fast-tracking diagnostics, treatments and vaccinations in future pandemics without compromising patient safety.
• Reflect on what has been learned from innovative and collaborative approaches during the COVID-19 pandemic that can be used for future pandemics.

Moderator:
- Chris John, FIP Lead for Data and Intelligence, UK

Panellists:
- Louise Druedahl, Researcher University of Copenhagen, Denmark
- N Udupa, Research Director Shri Dharmasthala Manjunatheshwara University, India
- Yvonne Perrie, Professor of Drug Delivery University of Strathclyde, UK

This event will discuss pharmacists’ roles in infectious & tropical disease prevention, and management by improving pharmacists’ knowledge in these diseases as well as showcasing practices across different countries with regards to policy, pharmaceutical care and services delivery and digital health applications across Africa in the context of infectious and tropical diseases.
Pharmacists are uniquely positioned to provide a wide array of services to prevent, and manage infectious and tropical diseases. This event aims to improve pharmacists' knowledge, improve pharmaceutical services delivery and overall health outcomes of the public in the context of infectious & tropical disease.

Learning objectives
1. Improve knowledge of pharmacists in the scope of infectious & tropical diseases as well as anti-infectives within the African region;
2. Showcase practices across different countries with regards to policy, pharmaceutical care and services delivery and digital health applications in the context of infectious & tropical diseases as well as anti-infectives within the African region;
3. Identify the needs and priorities of pharmacists in the prevention and management of infectious & tropical diseases within the African region.

Moderator:
- Jocelyn Chaibva, Vice president African Pharmaceutical Forum, Zimbabwe

Facilitators:
- Nilhan Uzman, FIP Lead for Education and Primary Health Policies, Turkey
- Alison Etukakpan, FIP Educational Partnership Specialist, Nigeria

Guests:
- Mirfin Mpundu, Director ReAct Africa, Kenya
- Natalie Schellack, Head of the Department of Pharmacology, University of Pretoria, South Africa
- Arinola Joda, Associate Professor University of Lagos, Nigeria

This event will discuss pharmacists’ roles in infectious & tropical disease prevention, and management by improving pharmacists’ knowledge in these diseases as well as showcasing practices across different countries with regards to policy, pharmaceutical care and services delivery and digital health applications across Africa in the context of infectious and tropical diseases.
Pharmacists are uniquely positioned to provide a wide array of services to prevent, and manage infectious and tropical diseases. This event aims to improve pharmacists' knowledge, improve pharmaceutical services delivery and overall health outcomes of the public in the context of infectious & tropical disease.

Learning objectives
1. Improve knowledge of pharmacists in the scope of infectious & tropical diseases as well as anti-infectives within the African region;
2. Showcase practices across different countries with regards to policy, pharmaceutical care and services delivery and digital health applications in the context of infectious & tropical diseases as well as anti-infectives within the African region;
3. Identify the needs and priorities of pharmacists in the prevention and management of infectious & tropical diseases within the African region.

Moderator:
- Jocelyn Chaibva, Vice president African Pharmaceutical Forum, Zimbabwe

Facilitators:
- Nilhan Uzman, FIP Lead for Education and Primary Health Policies, Turkey
- Alison Etukakpan, FIP Educational Partnership Specialist, Nigeria

Guests:
- Mirfin Mpundu, Director ReAct Africa, Kenya
- Natalie Schellack, Head of the Department of Pharmacology, University of Pretoria, South Africa
- Arinola Joda, Associate Professor University of Lagos, Nigeria

The first of December commemorates World AIDS day and this year FIP will join this campaign by launching a toolkit for pharmacists on HIV prevention, screening and management. It is now possible to effectively prevent the transmission of HIV through pharmacological strategies (preexposure and postexposure prophylaxis). New HIV tests have also become available, including point-of-care tests and self-tests. Pharmacists’ expertise and accessibility can be leveraged for a variety of important roles in the prevention and screening of HIV infections. Join this event to learn about these roles and be inspired by examples from different countries.

By the end of the session participants should be able to:
• Understand the roles pharmacists can play in HIV prevention, screening and management
• Recognise some resources and tools that pharmacists can use in this area
• Find and use the FIP toolkit on HIV prevention, screening and management

Moderator:
- Sham Moodley, FIP CPS Exco Member, Pharmacist Pharmaceutical Society of South Africa/Independent Community Pharmacy Assoc (ICPA), South Africa

Panellists:
- Rúben Viegas, FIP Practice Development and Transformation Projects Coordinator, Portugal
- Ali Ahmed, Ph.D. Final Year Student (Clinical Pharmacy) Monash University Malaysia, Malaysia
- Alicia Krüger, Clinical pharmacist Brazilian federal council of pharmacy, Brazil
- Elise HARO-BRUNET, Employed pharmacist CESPHARM (prevention committee) / French Chamber of pharmacists, France
- Romeo Ongpoy Jr, Dean Emilio Aguinaldo College - Cavite Campus, Philippines
- Katrina F. Ortblad, Assistant Professor Fred Hutchinson Cancer Research Center, USA
- Hamish Bowden, Senior Clinical Pharmacist (HIV & Sexual Health) The Albion Centre NSW Health, Australia

Long covid, also known as post COVID-19 condition, is estimated to affect 10-20% of people who develop COVID-19. While the majority go on to fully recover, this group of people suffer a variety of physical, physiological and cognitive symptoms for many weeks, months and sometimes longer. The condition can be debilitating and recovery requires a holistic and personalised care approach, including pharmaceutical care.

This event by FIP aims to explore in more depth what long covid is, what the key characteristics and symptoms are and how these symptoms can be managed in the pharmacy. The panellists include a public health expert on long-covid-19, a clinical pharmacist who is recovering from long covid, a physiotherapist and more.

Learning objectives:
1. Describe the key characteristics and symptoms of long COVID-19
2. Understand the latest research and evidence concerning treatment and care
3. Discuss ways long covid symptoms can be managed in the pharmacy
4. Identify the importance of pharmacists' understanding of the condition and care needs

Moderator:
- Leonila Ocampo, FIP Community Pharmacy Section, Asia Pacific Institute for Medication Management Philippine Pharmacists Association, Philippines

Panellists:
- Darren Brown, Clinical Academic Physiotherapist, Chelsea and Westminster Hospital NHS Foundation Trust; Long COVID Physio, United Kingdom
- Rani Khatib, Consultant Cardiology Pharmacist and Associate Professor University of Leeds, United Kingdom
- Lucette Cysique, Associate Professor The University of New South Wales, Australia

Competent pharmaceutical workforce is vital to ensure healthy lives and promote well-being. This is aligned with the FIP Development Goals. Competency-base education (CBE) model became a core of healthcare professions education and training globally.

Some challenges are encountered relating to the implementation of CBE model to initial pharmacy and pharmaceutical education and training (IPET). Hence, FIPEd team has developed the handbook to support pharmacy leaders and educators for their journey of CBE implementation in their education programme. The webinar will officially launch the handbook and go through the background of the handbook development and how it can help them implement CBE.


Learning objectives:
• Understand the importance of CBE in pharmacy and pharmaceutical education
• Describe the structure of FIPEd CBE Implementation Handbook
• Identify how the Handbook can support oneself for their CBE implementation journey

Moderators:
- Marwan Akel, Projects Manager – FIP Workforce development, evidence & impact Journal Editor – Pharmacy Education Journal (PEJ), Lebanon
- Dalia Bajis, FIP Lead for Provision & Partnerships, Bahrain

Panellists:
- Naoko Arakawa, Assistant Professor in International Pharmacy University of Nottingham, UK
- Jessica McMullen, Pharmacist and PhD Student University of Nottingham, UK
- Andries Koster, Associate Professor of Pharmacology Dept. Pharmaceutical Sciences, Utrecht University, The Netherlands
- Pierre Moreau, Professor of pharmacology and therapeutics College of pharmacy Kuwait University, Kuwait
- Shaun Gleason, Global Lead for Academic Capacity, FIP Workforce Development Hub, Assistant Dean for Distance Degrees and Programs; Associate Professor of Clinical Pharmacy University of Colorado Skaggs School of Pharmacy, USA

Our final event will celebrate the success of the AMS in Action Webinar series as we reflect on the great work being done globally to tackle AMR. 

We will showcase our competition winners who will share their innovative ideas and tools to help support AMS and prevent the spread of AMR. 

Join us in our Call to Action! Make a pledge with Antibiotic Guardian about how you’ll make better use of antibiotics and help save these vital medicines from becoming obsolete.

With the potential to be the next ‘silent’ pandemic, antimicrobial resistance (AMR) is a global threat. The ONE FIP Commitment to AMR and antimicrobial stewardship (AMS) includes actions for education, practice, scientific research and workforce development. These commitments will also enable themes to be actioned across nations and regions. FIP commits to increase the awareness of AMR, strengthen AMS and support for evidence-based interventions. With two events on 21 and 22 November, in the form of workshops, FIP aims to:
• Provide education and development
• Provide the priority FIP Development Goals (FIP DGs) areas and the priority commitments to devise the 2023 plans.
• Inform the 2023 Commitment to Action and Health Ministers Summit.

Learning objectives:
With a regional focus on the Eastern Mediterranean, European and Americas regions, participants in this workshop will be able to:

1. Outline regional educational and development headline needs in AMR and AMS,
2. Outline FIP DGs areas and the priority commitments for pharmacists’ organisations,
3. Input on how they can contribute to the FIP AMR 2023 plans.

Chair:
- Manjiri Gharat, FIP Vice President & Chair of the FIP Commission on AMR, India

Guest:
- Victoria Rutter, Executive Director, CPA, UK

Facilitators:
- Dalia Bajis, FIP Lead for Provision and Partnerships, Bahrain
- Chin-Yen Yeo, Senior AMS Pharmacist, Concord Repatriation General Hospital, Australia
- Fiona Doukas, Senior Project Officer, ACSQHC, Australia

Panellists:
- Usman Ebubakar, Senior Lecturer, Universiti Sains Malaysia, Malaysia
- Michelle Gijzelaar, National Clinical Pharmacy Manager, Life Healthcare, South Africa
- Onyeka Chinwuba Obidiegwu, Lecturer, Nnamdi Azikiwe University, Awka, Nigeria
- Roop Gupta, Vice President, IPA, India
- Syamhanin Adnan, Leader, AMS Focus Group for Pharmacist, MPS, Malaysia
- Fitria Nur Hidayah, Clinical Pharmacist, Cipto Mangunkusumo Hospital, Indonesia

With the potential to be the next ‘silent’ pandemic, antimicrobial resistance (AMR) is a global threat. The ONE FIP Commitment to AMR and antimicrobial stewardship (AMS) includes actions for education, practice, scientific research and workforce development. These commitments will also enable themes to be actioned across nations and regions. FIP commits to increase the awareness of AMR, strengthen AMS and support for evidence-based interventions. With two events on 21 and 22 November, in the form of workshops, FIP aims to:
• Provide education and development
• Provide the priority FIP Development Goals (FIP DGs) areas and the priority commitments to devise the 2023 plans.
• Inform the 2023 Commitment to Action and Health Ministers Summit.

Learning objectives:
With a regional focus on the Eastern Mediterranean, European and Americas regions, participants in this workshop will be able to:

1. Outline regional educational and development headline needs in AMR and AMS,
2. Outline FIP DGs areas and the priority commitments for pharmacists’ organisations,
3. Input on how they can contribute to the FIP AMR 2023 plans.

As busy health care professionals we are always looking for tools and resources to make our jobs more efficient and effective. This session will look at some tools and resources that are used in practice across the globe to support AMS initiatives, inspiring you to think about what you could develop or apply in your own practice to help support the more appropriate use of antimicrobials with both patients and colleagues.

Learning objectives:
● Discuss innovative tools for sharing information
● Learn about the development and deployment of an innovative and fun teaching tool
● Describe how you can use different platforms to engage healthcare professionals and communities

Moderator:
- Meghna Joshi-von Heyden, Strategic Lead: Partnerships and Advocacy Commonwealth Pharmacists Association, Switzerland
- Maxencia Nabiryo, Project Manager Commonwealth Pharmacists Association, Uganda
- Israel Sefah, Lecturer and Specialist Pharmacist, Department of Pharmacy Practice in the School of Pharmacy of the University of Health and Allied Sciences, Ghana
- Akello Zainab, Lead pharmacist and AMS Technical Lead Gulu Regional Referral Hospital, Uganda
- Andrew Balamba, Pharmacist University Teaching Hospital, Zambia
- Jessica Fraser, Programmes Coordinator Tropical Health & Education Trust, UK
- Ugyen Tashi, Chief Program Officer Essential Medicines and Technology Division (EMTD), Ministry of Health, Bhutan
- Bridget Kebirungi, Project Manager Commonwealth Pharmacists Association, Uganda

Sesión III: Estructura Bioexención en Colombia

Para abogar por una implementación más amplia y armonizada de bioexenciones basadas en el sistema de clasificación biofarmacéutica (BCS) en los países de América Latina, la FIP está apoyando a los líderes regionales en la sensibilización sobre esta vía reguladora basada en la ciencia diseñada para acelerar la aprobación del mercado de productos farmacéuticos genéricos seguros y eficaces. La segunda parte de esta serie de seminarios web diseñados específicamente para la región de América Latina destaca ejemplos de vías de aprobación regulatoria de bioexenciones basadas en BCS que se implementan actualmente en países seleccionados de América Latina. Los expertos abordarán la base legislativa de las regulaciones de bioexenciones y discutirán las oportunidades de armonización dentro de la región.

Este webinar tiene los objetivos:

• Diferenciar entre la bioequivalencia in vivo y las estrategias reguladoras de bioexención basadas en BCS para la aprobación de medicamentos genéricos.
• Comprender las implicaciones para la salud pública de la vía reguladora de la bioexención basada en BCS.
Delinear oportunidades y desafíos para la implementación de un proceso armonizado de aprobación regulatoria de bioexenciones dentro de la región de América Latina.
Delinear las contribuciones de solubilidad, permeabilidad y disolución para aplicaciones de bioexención basadas en BCS.

Moderadora:
- Talita Ferreira, Coordinadora de Proyectos de bioexención en Latinoamérica International Pharmaceutical Federation (FIP), Brazil

Panelista:
- Diego Alejandro Gutierrez Triana, Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA) Director de medicamentos y productos biológicos, Colombia

The US public benefits from reduced costs and improved access to treatment enabled by availability of generics drug products. Patients offer a unique perspective when advocating for accessibility to high-quality and affordable generics. As critical stakeholders, it is important that the FDA Office of Generic Drugs (OGD) captures patient perspectives, needs, and priorities to help better inform patients. This session will explore the role of patients in generic drug development, OGD’s patient engagement sessions to date and the opportunities that can be used to improve patient engagement.

Learning objectives:

• The FDA’s perspectives on patient’s role in drug development
• How Office of Generic Drugs (OGD) is working on patient engagement

Moderator:
- Mathew Cherian, FIP IPS ExCo Member for Webinars, Consultant, USA

Co-moderator :
- Maria Mantziri, FIP IPS ExCo Associate, Pharmacist, Pharmacovigilance Scientist, Greece

Panellist:
- Sarah Ibrahim, Associate Director CDER, Office of Generic Drugs, FDA, USA

Vaccination is one of the most effective measures to prevent disease transmission and protect populations from a variety of diseases that heavily impact individuals and health systems. Overall, through the provision of person-centred pharmaceutical services, pharmacists play a key role ensuring healthy lives and promoting wellbeing, as well as promoting more effective, rational, and widespread use of vaccines. Among the different special-risk population groups for vaccine-preventable diseases, people living with diabetes have particular vaccination needs that will be highlighted at this event.

By the end of the session participants should be able to:
- Understand the most important vaccines for people living with diabetes
- Recognise the role of pharmacists in promoting vaccination to people living with diabetes
- Discuss strategies for pharmacists to support people living with diabetes with their vaccination needs.

Moderator:
- Astrid Czock, CEO QualiCCare, Switzerland

Panelists:
- Marco Goeijenbier, Medical doctor internal medicine and intensive care, Spaarne Gasthuis Haarlem/Hoofddorp & Erasmus Medical Center Rotterdam, The Netherlands
-  Sallianne Kavanagh, Senior Lecturer- Clinical Pharmacy and Pharmacy Practice. Advanced Clinical Pharmacist,  University of Huddersfield and Sheffield Teaching Hospitals NHSFT, United Kingdom
- Iryna Vlasenko, Vice president International Diabetes Federation, Ukraine
- Francisco Javier Jiménez Ramírez, Professor / Pharmacist University of Puerto Rico School of Pharmacy, Puerto Rico

Pharmacists are well placed as members of the multidisciplinary team but are also key and accessible healthcare professionals for members of the public. Webinar 4 will explore and consider how pharmacists can support AMS in community practice around the globe.

Learning objectives:
- Define how pharmacists working in the community can support AMS and IPC initiatives as part of the wider multidisciplinary team;
- Explain how different forms of education and awareness raising can support the AMR agenda in the community setting;
- Discuss learning opportunities for reducing the risks of AMR that can be harnessed from experiences in treating and managing other infectious diseases such as TB, malaria and HIV;
- Describe how you can inspire and engage members of the community in a call to action on AMR;
- Demonstrate how AMR can impact patients at an individual, community and global level; and
- Apply behaviour change techniques to improve AMS initiatives in community practice.

Moderators

- Claire Brandish, Senior Antimicrobial Resistance Technical Advisor, The Commonwealth Pharmacist Association
- Dalia Bajis, Lead for Provision and Partnerships, International Pharmaceutical Federation

Speakers

- Amy Chan, Clinical Academic Pharmacist, University of Auckland
- Tadeo Tumusiime, National Programs Coordinator, Makerere University School of Public Health
- Erick Venant, Founder- Roll Back Antimicrobial Initiative & Lead Coordinator-BSAC’s-Stop Superbugs, Roll Back Antimicrobial Initiative
- Manjiri Gharat, Principal of K M Kundnani Pharmacy Polytechnic, VP of Indian Pharmaceutical Association and VP of FIP, K M Kundnani Pharmacy Polytechnic, FIP and IPA
- David Musoke, Senior Lecturer, Makerere University School of Public Health
- Ella Balasa, Patient Advocate and Consultant

As we approach a post-pandemic world, the global supply chain has been greatly influenced by various factors. Many different drug and product shortages have been exacerbated in recent years due to supply chain issues. Through this webinar, we want to give a better overview of understanding the current global supply chain, current threats to the supply chain such as drug shortages, natural disasters, counterfeit medicines, and how to create a resilient supply chain as we move forward in society. We also want to emphasize the value of a pharmacist in this area and the difference they can make.

Learning Objectives:
1. Describe the current global pharmacy supply chain
2. Compare the contrast the different threats to the pharmacy supply chain such as drug shortages, natural disasters, and counterfeit medicines
3. Understand how these threats can interrupt the supply chain from each panel member’s perspective/countries
4. Outline how to create a resilient supply chain and future endeavours taking place to protect the supply chain (i.e., automation and technology)

Moderator:
- Rob Moss, PharmD, Immediate past president, FIP Hospital Pharmacy Section, FIP, European Association of Hospital Pharmacists, The Netherlands

Panellists:
- Yuh Lih Chang, PhD, RPh Director, Department of Pharmacy, Taipei Veterans General Hospital; Principal Investigator, National Drug Shortage management Project; Associate Professor, National Yang-Ming Chiao-Tung University, Taiwan Veterans General Hospital, National Yang-Ming Chiao-Tung University, Taiwan
- Dr. Sohail Fitieh, Ph.D, MS PLA, RPh, Pharmacy & Supply Chain Consultant, United Arab of Emirates
- Michael Ganio, Pharm.D., M.S., BCPS, FASHP, Senior Director, Pharmacy Practice and Quality, American Society for Health-System Pharmacists, USA

What methods and data can be captured to elucidate how antimicrobials are used in different healthcare settings? How do we know if antimicrobials are being used appropriately and whether there is scope to make improvements? Webinar 3 will consider point prevalence data to understand antimicrobial use, how the data can be utilised to implement change and how to embed that change to create sustainable action.

Learning objectives:

• Define the Global Point Prevalence Survey tool and discuss the benefits of using this for data capture;
• Appraise different tools for antimicrobial use data capture and understand the pros and cons of each;
• Explain challenges to data capture and how to work around these;
• Examine how local data can be used to drive positive changes and support AMS initiatives; and
• Recognise how continuous quality improvement methodology can be used to help with Point Prevalence Survey data collection and to bring about sustainable behaviour changes as a result.

The FIP Development Goal 3 (Quality Assurance) Leads have developed a pharmacy education quality assurance tool. It can be used as a self-assessment tool, and for data collection to better understand quality assurance of pharmacy education programmes in different countries around the world.

The questions relate to the pharmacy degrees for initial entry to practice and/or licensure of pharmacists, reflected in three core sections:
1. Accreditation processes and accrediting bodies
2. Standards for quality assurance
3. Views on the value, relevance and outcomes of accreditation in the country

Learning Objectives:
1. To provide the rationale for conducting the FIP Quality Assurance in Pharmacy Education survey
2. To describe the three core sections in the QA tool
3. To provide information on completing the survey and potential benefits

Moderator:
- Abby A. Kahaleh, PhD, MS, BPharm, MPH, FAACP Tenured Faculty & Board of Trustees Faculty Roosevelt University College of Science, Health, & Pharmacy, USA

Panellists:
- Abeer M. AlGhananeem, DG3 Global Lead at FIP Workforce Development Hub, Associate Dean and Professor Sullivan University College of Pharmacy and Health Sciences, USA
- Banan Mukhalalati, Global lead for FIP Development Goal 3: quality assurance Assistant Professor Qatar University, Qatar

How nutrition impacts heart health is the focus of this event, the last and final one in the 'Food for thought: Pharmacists' role in healthy nutrition.' The webinar aims to examine the interlinks between nutrition and heart health, its role in the prevention and management of cardiovascular diseases, how pharmacy-based nutrition services can support patients with heart conditions.

The event aims to:

• Understand how nutrition impacts heart health
• Describe the importance of pharmaceutical care for heart health with a focus on supplements
• Highlight the important role of pharmacists in improving heart health and preventing cardiac disease.

Moderator:
- Jaime Acosta, FIP-CPS Professional Secretary, Community pharmacist Farmacia Acosta, Spain

Panellists:
- Philip Calder, President, Federation of European Nutrition Societies, Head of the School of Human Development and Health at the University of Southampton, UK
- Inês Nunes da Cunha, FIP Practice Development and Transformation Projects Manager, Portugal
- Esraa Altawil, Consultant Clinical Pharmacist King Saud University Medical City, Saudi Arabia

The FIP Global Competency Framework for Educators & Trainers in Pharmacy (FIP-GCFE) is a new tool to support advancement and competence development for our colleagues around the world, serving in any sector of pharmaceutical education. It was initiated by the Academic Pharmacy Section of FIP and created in collaboration across FIP, involving our leads, experts, volunteers across the Federation. This works is authored by experienced authors, global leaders in pharmaceutical education who are active in academic, practice and science fields of the pharmacy profession. The commitment to gather their knowledge, experience, values, and efforts, inspiring our colleagues to advance in the field of education, resulted in comprehensive and evidence-based framework.

Participants will be able to:
• Understand how to empower our individual and institutional members, focused on those involved in creating, delivering and assuring quality of pharmaceutical education.
• Learn about the valuable source of information and guide for educators and trainers in pharmacy at individual, organizational, national, and global levels.
• Understand how to use the Framework for their own personal and professional development.
• Start the application, research, and validation of the Framework
• Conduct the self-assessment of competencies according to the Framework

Moderators:
- Astrid Czock, FIP WDH Global Lead; CEO QualiCCare, Switzerland
- Marwan Akel, Projects Manager–Workforce development, evidence & impact Journal Editor – PEJ, Lebanon

Panellists:
- Arijana Mestrovic, FIP AcPS Vice President, FIP WDH Global lead for Competency Development; Director, Professional services
Pharma Expert, Croatia
- Mike Rouse, Director, International Services Accreditation Council for Pharmacy Education. USA
- Martin Charles Henman, FIP AcPS ExCO member Adjunct Assoc. Prof. Trinity College Dublin, Ireland
- Ian Bates, Chair of pharmacy education-University College London, UK
- Catherine Duggan, FIP CEO, Netherlands

Pharmacists have key roles in hospital multidisciplinary teams. Webinar 2 will explore how pharmacists can play a lead role in these teams and drive AMS initiatives in their place of work. How can we implement small day-to-day changes that lead to better patient outcomes? Learn more about the importance of collaboration in hospitals between healthcare professionals and how pharmacists fit into this collaborative work.

Learning objectives:

- Explain the importance of governance structures for successful AMS programmes;
- Learn how to set up medicines and therapeutics subcommittees and infection prevention control subcommittees; and
- Recognise the impact of AMR on patients when treatment fails.

Moderator:
- Sam Weston, Senior Project Manager SPAR, Commonwealth Pharmacists Association-UK

Guests:
- Freddy Eric Kitutu, Senior Lecturer Makerere University, Uganda
- Mary Millard, USA
- Elaine Cloutman-Green, Consultant Clinical Scientist, Deputy Director of Infection Prevention and Control and Lead Healthcare Scientist, Great Ormond Street Hospital for Children, NHS Foundation Trust, UK
- Abraham Weeks, Senior Technical Specialist, Organization of Eastern Caribbean States Pharmaceutical Pooled Procurement Unit Organization of Eastern Caribbean States Commission (OECS Commission), St Lucia
- Andrea Kwa Lay Hoon, Assistant Director (Research)/Specialist Pharmacist (Infectious Diseases)/Director of Infectious Diseases Pharmacotherapy Residency. Associate Professor Singapore General Hospital & Duke-NUS Medical School, Department of Emerging Infectious Diseases/NUS Pharmacy, Singapore

This special event is held during a week which marks two significant dates for global health. We will have passed the 1000 days since 30 January 2020 when the World Health Organization declared the COVID-19 outbreak at the time as a Public Health Emergency. The same week will also mark the 4th anniversary since the world, including FIP, came together in Astana in 2018 to endorse the new Declaration of Astana emphasizing the critical role of primary health care. Join us on this special launch event on pandemic preparedness to learn about global pharmacy’s response to COVID-19 and discuss the important of resilient pharmacy and health systems.

Learning objectives:
1. Understand how FIP supported (and continues to support) its members during the pandemic
2. Describe how pharmacy leadership bodies responded to the pandemic across the world
3. Discuss country best practices and lessons for future pandemic preparedness
4. Learn about FIP’s map of primary health care, focusing on strengthening health systems and recovery

Moderator:

- Lina Bader, FIP Lead for Equity, Sustainability Policy and Development, Saudi Arabia

Panellists:
- Mariet Eksteen, Professional Development and Support, Pharmaceutical Society of South Africa (PSSA), South Africa
- Hala Sacre, CEO, INSPECT-LB, Lebanon
- Clare Fitzel, Head of Professional Services, Irish Pharmacy Union, Ireland
- Teresa Almeida, Member of the board of directors, Associação Nacional das Farmácias, Portugal
- Mary Ann Sant Fournier, President, Malta Chamber of Pharmacists, Malta
- Leonor Soares, Leonor Soares, International Affairs, Portuguese Pharmaceutical Society, Portugal
- Nobuo Yamamoto, President, Japan Pharmaceutical Association, Japan
- Atsushi Toyomi, Executive Director, Japan Pharmaceutical Association, Japan
- Sofía Segura, Professor, University of Costa Rica and College of Pharmacists of Costa Rica, Costa Rica
- Roop Gupta, Chairman, Hospital Pharmacy Division and Vice President, India
- Jack Shen Lim, Treasurer, Malaysian Pharmacists Association, Malaysia
- Daragh Connolly, FIP Chair of BPP,  Ireland

FIP staff:
- Catherine Duggan, FIP Chief Executive Officer, UK/Netherlands
- Nour Eltahla, FIP Projects coordinator – Equity, sustainability policy and development, Saudi Arabia 
- Farah Aqqad, FIP Regional Engagement, Support and Development Manager, Jordan
- Sherly Meilianti, FIP Data and Intelligence Specialist, Indonesia 
- Nilhan Uzman, FIP lead for education and primary health care policies, The Netherlands

The World Health Organization estimate that 17.9 million people die from cardiovascular diseases each year, representing 32% of all global deaths. Pharmacists have a role to play in the prevention, care and management of cardiovascular diseases and their complications. FIP has developed a new handbook to support pharmacists and their organisations in providing a range of cardiovascular diseases-related services. This handbook — which will be launched at this event — also identifies the knowledge and skills that pharmacists require for the provision of such services, thus offering guidance to academic institutions and CPD providers. This handbook is part of the FIP Practice Transformation Programme on Non-Communicable Diseases.

Learning objectives:

1. Explore the role of pharmacists in the prevention, care and management of cardiovascular diseases and their complications;
2. Identify the challenges and opportunities for pharmacists in addressing cardiovascular diseases;
3. Identify the relevant knowledge and skills required for the delivery of cardiovascular diseases-related services.

Moderator:
- Paul Sinclair, Chair Board of Pharmaceutical Practice FIP, Australia

Panellists:
- Jean-Luc Eiselé, CEO World Heart Federation, Geneva, Switzerland
- Pedro Amariles, Full professor and researcher on Pharmaceutical Care and Clinical Pharmacy Universidad de Antioquia, Colombia
- Francesca Wirth, Senior Lecturer Department of Pharmacy, University of Malta, Malta
- Inês Nunes da Cunha, FIP Practice Development and Transformation Projects Manager FIP, Portugal
- Dalia Bajis, FIP Lead for Provision and Partnerships, Australia

Summary of “Creating development goal indicators – bridging data and outcomes” events

FIP member organisations of each region across the globe, selected some of the FIP Development Goals which are the priorities of their region. Western Pacific region: DG 1 (Academic capacity), DG 2 (Early career training strategy), DG 4 (Advanced and specialist development), DG 7 (Advancing integrated services), DG 12 (Pharmacy intelligence), DG 19 (Patient safety), and DG 20 (Digital health).

FIP Global Pharmaceutical Observatory (GPO) team members have designed and developed indicators to support tracking progress towards the development goals.​ This globally validated list of indicators across all DGs will monitor progress worldwide and support each country in the process of transformation of their workforce, education, practice, and pharmaceutical science. FIP is developing a framework for selecting indicators and a monitoring and evaluating DGs.  This will enable the design of global Atlas (data visualisation) dashboards that will drive and inform improvement and monitor trends over time. 

The process for tracking the development goals is first is to select priority DGs by identifying general, broad areas where there are active, ongoing national policies or projects mapped to the FIP DGs. The next step is to select the right indicators. Indicators are useful to provide measurable progress towards DGs, identify areas that need attention and support continuous improvement. After that, a monitoring and evaluation framework can be developed. Lastly, continuous development can be provided by regularly updating Atlas dashboards to present how the data changes over time. Atlas dashboards can include an actionable overview of a limited set of key indicators with novel ways of bringing attention to those areas that are advancing the profession or experiencing challenges. These have significant potential to support regular reviews of DG progress and improve the data quality.

Western Pacific Panel Discussion on DG priorities and data requirements:

• There are 4 DGs that are the foundation of other DGs, specifically for Western Pacific but can also apply globally: 1) DG 1 (Academic capacity), 2) DG 5 (Competency development), 3) DG 9 (Continuing professional development strategies), 4) DG 6 (Leadership development).
• DG 12 (Pharmacy intelligence) is very important because much research is being undertaken but attention is needed on how to use the collected data, how it could be applied and operationalized.
• DG 18 (Access to medicines, devices, and services) is also a priority, because there is still a challenge to achieve equity and equality in terms of accessing their medicines devices and services.
• In terms of DG 1 (Academic capacity), Australia has 47 accredited pharmacy programs offered by 20 providers and 125 pharmacists per 100.000 people. However, about 40% workforce are less than 35 years old and there is an increased proportion on this population who do not intend to practice beyond the next 10 years. There is a need to find out why young people are leaving the profession and whether we have been investing sufficiently to support the young graduates to advance further in their career. The government needs to work together with professional bodies and academic institution to invest more in pharmacy education and training to meet the demands of current and future health care needs.
• The development in early career strategy such as residency training programs by Society of Hospital Pharmacy in Australia (SHPA), early career pharmacists (ECP) forum and communities of specialty interests (CSIS) are aligned with the DG 2 (Early career training strategy).
• It is much better to have longitudinal data and track things rather than a snapshot. There are some readily available data such as the number of students coming in and go out successfully that might reflect academic capacity. There is a need for a common set of assessment that can be used across the region.
• For DG 7 (Advancing integrated services), we need to look at what policies and strategies are needed for strengthening and transforming pharmacy workforce education and systematic training on trainers and educators.
• There are some DGs that can be quantified numerically for the monitoring process such as in DG 9 (Continuing professional development strategies) we can count the attendance in continuing professional development events as a ratio to the total membership of the profession.

Summary of “Creating development goal indicators – bridging data and outcomes” events

FIP member organisations of each region selected some of the FIP Development Goals which are the priorities of their region. Eastern Mediterranean region: DG 2 (Early career training strategy), DG 5 (Competency development), DG 9 (Continuing professional development strategies), DG 13 (Policy development), and DG 19 (Patient safety).

FIP Global Pharmaceutical Observatory (GPO) team members have designed and developed indicators to support tracking progress towards the development goals.​ This globally validated list of indicators across all DGs will monitor progress worldwide and support each country in the process of transformation of their workforce, education, practice, and pharmaceutical science. FIP is developing a framework for selecting indicators and a monitoring and evaluating DGs.  This will enable the design of global Atlas (data visualisation) dashboards that will drive and inform improvement and monitor trends over time. 

The process for tracking the development goals is first is to select priority DGs by identifying general, broad areas where there are active, ongoing national policies or projects mapped to the FIP DGs. The next step is to select the right indicators. Indicators are useful to provide measurable progress towards DGs, identify areas that need attention and support continuous improvement. After that, a monitoring and evaluation framework can be developed. Lastly, continuous development can be provided by regularly updating Atlas dashboards to present how the data changes over time. Atlas dashboards can include an actionable overview of a limited set of key indicators with novel ways of bringing attention to those areas that are advancing the profession or experiencing challenges. These have significant potential to support regular reviews of DG progress and improve the data quality.

East Mediterranean Region Panel Discussion on DG priorities and data requirements:

• In Qatar, there is a gap in DG 2 (Early career training strategy) i.e. there is a need for training for the early career pharmacists. This also aligns with the competency framework, which is needed for both early graduated pharmacists and advanced pharmacists.
• Qatar have done well so far on DG 1 (Academic capacity) and DG 3 (Quality assurance). In terms of quality assurance, College of Pharmacy at Qatar University have gone through accreditation at Canadian Council for Accreditation of Pharmacy Programs (CCAP).
• The top priority is to develop a practice framework for pharmacist practitioners whether they are in early or advanced career.
• Data needed are the number of pharmacists in the country within different sectors, and whether they are following professional development program or certifying system for continuing their education. Currently Qatar also has a committee which is focusing on professional development not only for pharmacists but also for all health care profession in general. Qatar can also learn to create the framework from FIP and neighbouring countries such as Saudi Arabia.
• There is a gap between science, education and workforce which need to be connected in EMR. The competency of pharmacists at work is important. More efforts relating to pharmacy education are needed such as accreditation for the educational level, continuous education, certification, and competency framework as a standard. The variation in pharmacy education globally also needs to be unified.

To advocate for a broader and more harmonized implementation of Biopharmaceutical Classification System (BCS)-based biowaivers in Latin American countries, the FIP is supporting regional leaders in raising awareness of this science-based regulatory pathway designed to accelerate market approval of safe and effective generic pharmaceuticals. The second part of this series of webinars designed specifically for the Latin American region highlights examples of BCS-based biowaiver regulatory approval pathways currently being implemented in select Latin American countries. Experts will address the legislative basis for biowaiver regulations and discuss harmonization opportunities within the region.

This webinar has the objectives:

• Differentiate between in vivo bioequivalence and BCS-based biowaiver regulatory strategies for generic drug approval.
• Understand the public health implications of the BCS-based biowaiver regulatory pathway.
• Outline opportunities and challenges for the implementation of a harmonized biowaiver regulatory approval process within the Latin American region.
• Outline solubility, permeability, and dissolution contributions for BCS-based biowaiver applications.

Moderator:
Talita Ferreira, Coordinator Latin America Biowaiver Project International Pharmaceutical Federation (FIP), Brazil

Panelist:
Eduardo Agostinho Freitas Fernandes, Specialist in health regulation and surveillance ANVISA - Brazilian Health Regulatory Agency, Brazil

Para abogar por una implementación más amplia y armonizada de bioexenciones basadas en el sistema de clasificación biofarmacéutica (BCS) en los países de América Latina, la FIP está apoyando a los líderes regionales en la sensibilización sobre esta vía reguladora basada en la ciencia diseñada para acelerar la aprobación del mercado de productos farmacéuticos genéricos seguros y eficaces. La segunda parte de esta serie de seminarios web diseñados específicamente para la región de América Latina destaca ejemplos de vías de aprobación regulatoria de bioexenciones basadas en BCS que se implementan actualmente en países seleccionados de América Latina. Los expertos abordarán la base legislativa de las regulaciones de bioexenciones y discutirán las oportunidades de armonización dentro de la región.

Este webinar tiene los objetivos:

• Diferenciar entre la bioequivalencia in vivo y las estrategias reguladoras de bioexención basadas en BCS para la aprobación de medicamentos genéricos.
• Comprender las implicaciones para la salud pública de la vía reguladora de la bioexención basada en BCS.
• Delinear oportunidades y desafíos para la implementación de un proceso armonizado de aprobación regulatoria de bioexenciones dentro de la región de América Latina.
• Delinear las contribuciones de solubilidad, permeabilidad y disolución para aplicaciones de bioexención basadas en BCS.

Moderadora:
- Talita Ferreira, Coordinadora de Proyectos de bioexención en Latinoamérica International Pharmaceutical Federation (FIP), Brazil

Panelista:
- Andrés Figueroa Campos, Gerente SD Registro Sanitario de Productos Farmacéuticos Bioequivalentesy, ANAMED ISPch – Agencia Nacional de Vigilancia Sanitaria de Chile

In 2019, the FIP Advisory Committee for the Pharmacy Technician and Support Workforce Strategic Platform was established and took on the responsibility to host future Symposia. Since 2020, the Pharmacy Technicians’ Symposium has been hosted and delivered as a digital event to promote widespread access to this learning forum. The committee is once again pleased to host, on October 18th and 19th,, the 2022 Pharmacy Technicians’ Symposium. This digital event will offer 2 half day sessions showcasing global roles and practice models among the pharmacy technician workforce, built on a theme of resiliency and contribution by  working with other members of the pharmaceutical workforce toward recovery of the healthcare system. More here. 

Pharmacists have a key role in leading antimicrobial stewardship initiatives to help tackle antimicrobial resistance. In Webinar 1, you will learn more about the magnitude of this recognised global health threat, its impact on real life, and how our profession can overcome challenges and make the most of opportunities to work collaboratively and shine in this space.

Learning objectives:

• Identify the problem of AMR globally and some of the initiatives in place to tackle this;
• Describe the importance of multidisciplinary teams and the role pharmacists play within them in the context of AMS;
• Become familiar with how pharmacists from different geographical regions are helping to address AMR; and
• Recognise the impact of AMR on patients when treatment fails.

In 2019, the FIP Advisory Committee for the Pharmacy Technician and Support Workforce Strategic Platform was established and took on the responsibility to host future Symposia. Since 2020, the Pharmacy Technicians’ Symposium has been hosted and delivered as a digital event to promote widespread access to this learning forum. The committee is once again pleased to host, on October 18th and 19th,, the 2022 Pharmacy Technicians’ Symposium. This digital event will offer 2 half day sessions showcasing global roles and practice models among the pharmacy technician workforce, built on a theme of resiliency and contribution by  working with other members of the pharmaceutical workforce toward recovery of the healthcare system. More here. 

Summary of “Creating development goal indicators – bridging data and outcomes” events

FIP member organisations of each region selected some of the FIP Development Goals which are the priorities of their region.   Southeast Asia region: DG 12 (Pharmacy intelligence), DG 15 (People-centred care), and DG 19 (Patient safety).

FIP Global Pharmaceutical Observatory (GPO) team members have designed and developed indicators to support tracking progress towards the development goals.​ This globally validated list of indicators across all DGs will monitor progress worldwide and support each country in the process of transformation of their workforce, education, practice, and pharmaceutical science. FIP is developing a framework for selecting indicators and a monitoring and evaluating DGs.  This will enable the design of global Atlas (data visualization) dashboards that will drive and inform improvement and monitor trends over time. 

The process for tracking the development goals is first is to select priority DGs by identifying general, broad areas where there are active, ongoing national policies or projects mapped to the FIP DGs. The next step is to select the right indicators. Indicators are useful to provide measurable progress towards DGs, identify areas that need attention and support continuous improvement. After that, a monitoring and evaluation framework can be developed. Lastly, continuous development can be provided by regularly updating Atlas dashboards to present how the data changes over time. Atlas dashboards can include an actionable overview of a limited set of key indicators with novel ways of bringing attention to those areas that are advancing the profession or experiencing challenges. These have significant potential to support regular reviews of DG progress and improve the data quality.

Southeast Asian Region Panel Discussion on DG priorities and data requirements:

• The 21 DGs are aligned with the health system transformation in Indonesia, especially for DG 4 (Advanced and specialist development), DG 12 (Pharmacy intelligence and DG 20 (Digital health). DG 4 (Advanced and specialist development) is the most aligned DG in relation with transformation agenda on health human resources in Indonesia.
•  In Sri Lanka, the priority goals are DG 1 (Academic capacity), DG 2 (Early career training strategy), DG 5 (Competency development), and DG 9 (Continuing professional development strategies). DG 1 is important because Sri Lanka has different pathways of creating pharmacists with most of the other countries, there are 3 programs with different qualification.
• Sri Lanka needs is to collect the data of pharmacists working in different sectors, because all pharmacists are having the same certificate and this not mention the area of practice.
• Currently, Sri Lanka does not have a well-organized education and training program to support early career pharmacists, or a development framework to support career development and no continuing professional development program for pharmacists.
• All 21 DGs resonate with the needs in India. The priority areas are DG 12 (Pharmacy Intelligence), DG 15 (People-centred care) and DG 19 (Patient safety). Pharmacy council of India is maintaining the data about number of pharmacists and number of colleges which needs to be updated regularly and available to the policy makers as well as the people.
• India is currently developing the data regarding available pharmacists and their area of work.
• Indonesia needs the data of pharmacists that provide services across nation, their competencies profile and progress on the career. Indonesian Pharmacists Association already created the information system to provide the data on number of pharmacists, however, the data is still lacking the competencies profile and the progress on their career pathway for advanced practice perspective.

Despite a temporary drop in the incidence of seasonal influenza during the pandemic, it will continue to represent a heavy burden for healthcare systems and societies overall. In a post-pandemic scenario, it will be crucial to protect and further advance the progress that had been achieved globally in terms of flu vaccination rates. This event will discuss why flu vaccination remains a priority, and how co-administration of flu and COVID-19 vaccines can provide a convenient and effective solution for driving vaccination uptake for both diseases. The event will also explore how pharmacists can contribute to flu vaccination strategies.

By the end of the session participants should be able to:
• Understand the importance of flu vaccination, especially for vulnerable population groups, like the elderly
• Recognize the need for improving vaccination coverage rates for both the flu and COVID-19.
• Discuss pharmacists’ contribution to flu vaccination strategies.

Moderator:
- Lars-Åke Söderlund, FIP Vice President International Pharmaceutical Federation, Sweden

Panelists:
- Joshua A. Mott, Technical Advisor for Influenza and Pandemic Preparedness, WHO, Department of Epidemic and Pandemic Preparedness and Prevention, Switzerland
- Lyn Morgan, Coordinator, Policy & Communications group, Influenza Vaccines Suppliers International Federation of Pharmaceutical Manufacturers’ Associations, France
- Maria Mendes, Area Manager at the Centre for Medicines Information and Health Interventions (CEDIME) at the National Association of Pharmacies, Portugal National Association of Pharmacies, Portugal

Summary of “Creating development goal indicators – bridging data and outcomes” events

FIP member organisations of each region selected some of the FIP Development Goals which are the priorities of their region. Africa region: DG 1 (Academic capacity), DG 3 (Quality assurance), DG 9 (Continuing professional development strategies), and DG 18 (Access to medicines, devices, and services).

FIP Global Pharmaceutical Observatory (GPO) team members have designed and developed indicators to support tracking progress towards the development goals.​ This globally validated list of indicators across all DGs will monitor progress worldwide and support each country in the process of transformation of their workforce, education, practice, and pharmaceutical science. FIP is developing a framework for selecting indicators and a monitoring and evaluating DGs.  This will enable the design of global Atlas (data visualisation) dashboards that will drive and inform improvement and monitor trends over time. 

The process for tracking the development goals is first is to select priority DGs by identifying general, broad areas where there are active, ongoing national policies or projects mapped to the FIP DGs. The next step is to select the right indicators. Indicators are useful to provide measurable progress towards DGs, identify areas that need attention and support continuous improvement. After that, a monitoring and evaluation framework can be developed. Lastly, continuous development can be provided by regularly updating Atlas dashboards to present how the data changes over time. Atlas dashboards can include an actionable overview of a limited set of key indicators with novel ways of bringing attention to those areas that are advancing the profession or experiencing challenges. These have significant potential to support regular reviews of DG progress and improve the data quality.

African Region Panel Discussion on DG priorities and data requirements:

• All FIP DGs are relevant. The first and the main priority from FIP DGs is the DG 1 (Academic capacity). Academic capacity is the first step for developing the profession. There is a need to collect the data on education such as the number of people in academia, university lecturers, and hours of courses. The second one is the strong regulation for quality assurance of the medicines.
• In Ghana, there is a need to improve access to quality medicines (DG 18). DG 18 (Access to medicines, devices, and services) is the main priority in the continent.
• Three most prioritized goals are: 1) DG 4 (Advanced and specialist development), to enforce the law established in 2012; 2) DG 5 (Competency development) to standardize the competency of pharmacy graduates; 3) DG 20 (Digital health) to control substandard and falsified medicines.
• The Pharmacy Council of Ghana is also developing the e-pharmacy policy and subsequently have developed national electronic pharmacy platform.
• For DG 4 (Advanced and specialist development), there’s a need to get the baseline data in terms of available capacities and specialists. After having the baseline data as well as the needs assessment results, pharmacies can be trained based on their interests and we can track the implementation after the training.

Summary of “Creating development goal indicators – bridging data and outcomes” events

FIP member organisations of each region selected some of the FIP Development Goals which are the priorities of their region. European region: DG 1 (Academic capacity), DG 4 (Advanced and specialist development), DG 7 (Advancing integrated services), DG 13 (Policy development), DG 15 (People centred care), DG 19 (Patient safety), DG 20 (Digital health), and DG 21 (Sustainability in pharmacy).

FIP Global Pharmaceutical Observatory (GPO) team members have designed and developed indicators to support tracking progress towards the development goals.​ This globally validated list of indicators across all DGs will monitor progress worldwide and support each country in the process of transformation of their workforce, education, practice, and pharmaceutical science. FIP is developing a framework for selecting indicators and a monitoring and evaluating DGs.  This will enable the design of global Atlas (data visualization) dashboards that will drive and inform improvement and monitor trends over time. 

The process for tracking the development goals is first is to select priority DGs by identifying general, broad areas where there are active, ongoing national policies or projects mapped to the FIP DGs. The next step is to select the right indicators. Indicators are useful to provide measurable progress towards DGs, identify areas that need attention and support continuous improvement. After that, a monitoring and evaluation framework can be developed. Lastly, continuous development can be provided by regularly updating Atlas dashboards to present how the data changes over time. Atlas dashboards can include an actionable overview of a limited set of key indicators with novel ways of bringing attention to those areas that are advancing the profession or experiencing challenges. These have significant potential to support regular reviews of DG progress and improve the data quality.

European Region Panel Discussion on DG priorities and data requirements

• FIP DGs are aligned with national priorities, which also to achieve the United Nation’s health related Sustainable DGs. Nowadays there is an organizational shift which reduces the boundaries and encourage integrated care according to the patient needs, this is also one of the reasons why FIP DGs are really aligned to the national priorities.
• In the UK, DG 2 (Early career training strategy), DG 7 (Advancing integrated services) and DG 21 (Sustainability in pharmacy) resonates with the national needs.
• In Portugal, DG 5 (Competency development), DG 7 (Advancing integrated services) and DG 13 (Policy development) are the DGs that mostly aligned with three national priorities, which are to: 1) increase access to patient information, 2) guarantee successful implementation of pharmaceutical career in national health system, and 3) promote implementation and reimbursement of new pharmaceutical services.
• In Northern Cyprus, DG 9 (Continuing professional development strategies), DG 13 (Policy development), DG 19 (Patient safety), and DG 4 (Advanced and specialist development) are the DGs that are mostly resonates with the national priorities.
• Data needed to track the progress are: 1) quantitative and qualitative data of pharmacists’ placement in undergraduate curriculum, 2) competencies measurement and the real impact of pharmacists from holding a specific competency and 3) qualitative data regarding continuous professional development and specialists (i.e., sport pharmacists).

Summary of “Creating development goal indicators – bridging data and outcomes” events

FIP member organisations of each region selected some of the FIP Development Goals which are the priorities of their region. Americas region: DG 1 (Academic capacity), DG 3 (Quality assurance), DG 13 (Policy development), and DG 15 (People-centred care).

FIP Global Pharmaceutical Observatory (GPO) team members have designed and developed indicators to support tracking progress towards the development goals.​ This globally validated list of indicators across all DGs will monitor progress worldwide and support each country in the process of transformation of their workforce, education, practice, and pharmaceutical science. FIP is developing a framework for selecting indicators and a monitoring and evaluating DGs.  This will enable the design of global Atlas (data visualisation) dashboards that will drive and inform improvement and monitor trends over time. 

The process for tracking the development goals is first is to select priority DGs by identifying general, broad areas where there are active, ongoing national policies or projects mapped to the FIP DGs. The next step is to select the right indicators. Indicators are useful to provide measurable progress towards DGs, identify areas that need attention and support continuous improvement. After that, a monitoring and evaluation framework can be developed. Lastly, continuous development can be provided by regularly updating Atlas dashboards to present how the data changes over time. Atlas dashboards can include an actionable overview of a limited set of key indicators with novel ways of bringing attention to those areas that are advancing the profession or experiencing challenges. These have significant potential to support regular reviews of DG progress and improve the data quality.

Americas Region Panel Discussion on DG priorities and data requirements

• Progress was highlighted with DG 18 (Access to medicines, devices, and services), DG 19 (Patient safety) and DG 20 (Digital health). For DG 20, there are electronic health records and apps about Coronavirus information. Current needs are not only to generate new data but also to make more data available to public. However, this is limited by the regulatory agency.
• It is difficult to assess only specific DG priority because each of the DGs is often connected to another. For example, DG 15 (People centred care) is linked to DG 8 (Working with others), DG 7 (Advancing integrated services) and DG 11 (Impact and outcomes).
• In the Americas, there is often a lack of data related to the multi-employment of pharmacists. There is also lack of professionals presents in community pharmacy.
• There is a need for data related to pharmacies participation in immunization and occupation and renumeration related to gender.
• To implement strategic plans, we need the data before and after the implementation

The COVID19 pandemic has highlighted that we need better antiviral therapies, especially for respiratory viral diseases. We have developed inhalation therapies consisting of siRNA nanoparticles which inhibit the viral genome of coronaviruses. The advantage over vaccination is the therapeutic index for virus variants and new coronaviruses. Other so far undruggable targets are transcription factors which are often drivers of tumorigenesis. Accordingly, examples for pulmonary delivery of therapeutic RNA in asthma, targeting GATA-3, and in lung cancer, targeting mutated KRAS, will be discussed.

Learning objectives:
*siRNA nanoparticles for inhalation delivery
*Application to un- druggable targets like transcription factors

Moderator:
Mathew Cherian, ExCo Member, Industrial Pharmacy Section, Consultant-USA

Co-moderator:
Kaushik Desai, Associate ExCo Member, Industrial Pharmacy Section, Secretary General International Pharmaceutical Excipients’ Council of India-India

Panelist:
Olivia Merkel, Professor of Drug Delivery Ludwig Maxmillian University (LMU) Munich, Germany

This webinar is the second of the Precision Medicine Webinar Series, which will discuss the current state and future of precision medicine in research and practice, including the ongoing technological advances and challenges and opportunities for the pharmacy profession to address. This webinar will cover:
- Ongoing technological developments, including:
o Multi-omics
o Single-cell sequencing
o High-resolution imaging
o Combinatorial drug screens
o Biostatistics, machine learning and open software repositories
- Examples of clinical translation of the above technologies in a research context
- Thoughts on future directions of the field, and unaddressed gaps.

At the end of this session, participants will:
1. Have an awareness of some of the key technological advances driving the evolution of precision medicine.
2. Be familiar with some examples of its potential implementation
3. Be aware of current limitations and remaining challenges to be addressed


Co-Chairs:
-Donnacha Fitzgerald, FIP Technology Forum member, Predoctoral Fellow The European Molecular Biology Laboratory (EMBL) and Heidelberg University Hospital, Germany
-R. Stephanie Huang, Professor Department of Experimental and Clinical Pharmacology, University of Minnesota, USA

Panellists:
-Wolfgang Huber, Co-Director, Molecular Medicine Partnership Unit Group Leader ad Senior Scientist The European Molecular Biology Laboratory (EMBL), Germany
-Christoph Merten, Associate Professor Swiss Federal Institute of Technology Lausanne (EPFL), Switzerland

Cancer is the second leading cause of death globally, according to the World Health Organization. Prevention and early screening are crucial elements of interprofessional strategies to reduce the burden, morbidity and mortality associated with cancer, as are medication management for optimal outcomes, and patient support. Pharmacists have a key role to play in all these areas. At this digital event, FIP will be publishing a new handbook to support pharmacists and their organisations in providing a range of cancer-related services. In addition, the handbook will be accompanied by the knowledge and skills (K&S) reference guide in cancer which identifies the K&S that pharmacists require for the provision of such services, thus offering guidance to pharmacists, academic institutions and CPD providers. Both publications will be launched at this event, and they are part of the FIP Practice Transformation Programme on Non-Communicable Diseases.

Attendees will learn about:

1. The role of pharmacists in the prevention, screening, care and management of cancer;
2. Challenges and opportunities for pharmacists in implementing cancer-related services;
3. The knowledge and skills pharmacists need to acquire to support their role in the delivery of cancer-related services.

Moderator:

-Inês Nunes da Cunha, FIP Practice Development and Transformation Projects Manager FIP, Portugal

Panelists:
-Evelyn Handel, ISOPP President (2022-2024) International Society of Oncology Pharmacy Practitioners (ISOPP), USA
-Folakemi T. Odedina, Professor of Oncology Mayo Clinic Cancer Center, USA
-Matthew Hung, Clinical Staff Pharmacist St. Mary’s Hospital, Montreal West Island Integrated University Health and Social Services Centre, Canada
-Dalia Bajis, Lead for provision and partnerships FIP, Australia

Vaccination is one of the most effective measures to prevent disease transmission and help people remain healthy and retain functional ability as they grow older. Adopting a life-course approach to vaccination and providing convenient and accessible vaccination pathways for older adults is essential to achieve high vaccination coverage rates in this particular population group. Pharmacists increasingly offer reliable information and vaccination services around the world. Among the different special-risk population groups, older adults have specific vaccination needs that will be discussed in this event.

By the end of the session participants should be able to:
1. Understand the most important vaccines for older adults
2. Recognise the role of pharmacists in promoting vaccination to the elderly
3. Discuss strategies for the promotion of a life-course approach to vaccination

Moderator:
- Lina Bader, Lead for Equity, sustainability policy and development International Pharmaceutical Federation (FIP), Saudi Arabia

Panelists:
- Jean-Pierre MICHEL, Honorary Professor of Medicine University of Geneva, Switzerland
- David Sinclair, Chief Executive ILC. UK
- Jane Barratt, Secretary General International Federation on Ageing, Canada
- Ruggli Martine, President pharmaSuisse, Switzerland

Strengthening our patients' immune systems has never been more important, and healthy nutrition is one critical factor. This event focuses on how nutrition impacts immunity and its importance in supporting a strong and responsive immune system. It is the second event in the 2022 FIP series 'Food for thought: Pharmacists' role in healthy nutrition'.

Moderator:
Jaime Acosta, Community Pharmacist Farmacia Acosta- Spain

Panelists:
-Philip Calder, President, Federation of European Nutrition Societies Head of the School of Human Development and Health at the University of Southampton, United Kingdom
-Joanna Harnett, Senior Lecturer Sydney Pharmacy School, Australia
-Basma Abdulsamad, Clinical Pharmacist – MSc. Immunology and Allergy – Harvard Associate Alumni Medical Research Institute, Alexandria Egypt, Egypt

Asthma and chronic obstructive pulmonary disease are common chronic respiratory diseases (CRD) that affect millions of people worldwide. Pharmacists have a role to play in the prevention, care and management of CRD. FIP will be publishing a new handbook to support pharmacists and their organisations in providing a range of CRD-related services. This will be accompanied by a reference guide which identifies the knowledge and skills that pharmacists require for the provision of such services. Both publications will be launched at this event, and they are part of the FIP Practice Transformation Programme on Non-Communicable Diseases.

Attendees will learn about:
1. The role of pharmacists in the prevention, screening, care and management of chronic respiratory diseases and their complications;
2. Challenges and opportunities for pharmacists in addressing chronic respiratory diseases-related services;
3. The knowledge and skills pharmacists need for the delivery of chronic respiratory diseases services.

Moderator:
- Gonçalo Sousa Pinto, FIP Lead for Practice Development and Transformation, Portugal

Panelists:
- Ema Paulino, President Portuguese National Pharmacy Association, Portugal
- Siân Williams, Chief Executive Officer International Primary Care Respiratory Group (IPCRG), Scotland
- Inês Nunes da Cunha, FIP Practice Development and Transformation Projects Manager, Portugal
- Dalia Bajis, FIP Lead for provision and partnerships, Australia
- Richard Sammy, Pharmacist Changu Pharmacy Ltd, Kenya

Substandard and falsified medicines, along with a lack of adherence to medication regimens, pose a threat to public health worldwide. It is possible to deliver pharmaceutical care services that address these challenges using digital healthcare techniques and approaches. Globally, digital health faces many challenges and concerns, despite its potential to impact pharmaceutical care.
FIP and the Global Pharmaceutical Observatory are launching a new needs assessment programme entitled "How can digital health support national pharmaceutical care delivery? A regional and global assessment of priorities and challenges", with an emphasis on medication adherence and fighting SF medicines.
This regional and global needs assessment programme will include a series of six regional events, culminating in a private global roundtable and a summary report.

Aim:
Facilitate a regional discussion about ongoing digital health interventions or solutions that detect, report, and act against false or substandard medicines, and how to facilitate patient adherence, as well as the challenges leadership bodies and nations face in implementing digital health solutions in pharmaceutical care delivery in the Western Pacific.

Inequity has been identified as one of the most serious issues in education worldwide, with multiple causes and consequences. Recent evidence and findings from FIP research indicate that inequities in pharmaceutical education need to be addressed, and this FIP toolkit for addressing inequities in pharmaceutical education intends to motivate, assess, and inform forward thinking changes targeted at transforming pharmaceutical education through addressing inequities globally, across all regions and locally.

At the end of this session, participants will:
1. Learn about the vital inequity themes that impact pharmaceutical education;
2. Understand the importance of having equitable pharmaceutical education;
3. Discuss with the toolkit authors and high-level speakers how to take action towards enabling equitable pharmaceutical education nationally, regionally and globally

Moderator:
- Ralph J. Altiere, FIPEd Chair FIP and University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, USA

Guests:
-Catherine Duggan, FIP CEO, The Netherlands

Panelists:
- Nilhan Uzman, FIP Lead for education and primary health care policies, The Netherlands
- Alison Ubong Etukakpan, FIP Educational Partnership Specialist, Nigeria
- Karima Bennara, Chairperson of pharmacy education, International Pharmaceutical Students Federation, Algeria
- Khalid Garba Mohammed, Post doctoral Fellow, Pharmaceutical Engineering Group, School of Pharmacy, Queens University Belfast, UK
- Oliver Grundmann, Clinical Professor The College of Pharmacy, University of Florida, USA
- Neelaveni Padayachee, Senior lecturer and Researcher Department of Pharmacy and Pharmacology, Pharmacy Practice Division, The University of Witwatersrand, South Africa
- Aysu Selcuk, FIP Education and Primary Health Care Policies Specialist, Turkey
- Dalal Hammoudi, Associate Dean for Assessment Lebanese International University, School of Pharmacy, Lebanon

Substandard and falsified medicines, along with a lack of adherence to medication regimens, pose a threat to public health worldwide. It is possible to deliver pharmaceutical care services that address these challenges using digital healthcare techniques and approaches. Globally, digital health faces many challenges and concerns, despite its potential to impact pharmaceutical care.

FIP and the Global Pharmaceutical Observatory are launching a new needs assessment programme entitled "How can digital health support national pharmaceutical care delivery? A regional and global assessment of priorities and challenges", with an emphasis on medication adherence and fighting SF medicines.

This regional and global needs assessment programme will include a series of six regional events, culminating in a private global roundtable and a summary report.

In this regional event we will facilitate a regional discussion about ongoing digital health interventions or solutions that detect, report, and act against false or substandard medicines, and how to facilitate patient adherence, as well as the challenges leadership bodies and nations face in implementing digital health solutions in pharmaceutical care delivery in the Americas.

Moderator:
- Magaly Rodrigu, Vice president Pharmaceutical Forum of the Americas, USA

Panelists:
- Patricia Klahn Acuña, Clinical Pharmacist- Hospital Carlos Van Buren, Chile
- Ilisa Bernstein, Interim Executive Vice President and CEO American Pharmacists Association, USA
- Natalia Sancho-Vargas, Colegio de Farmacéuticos de Costa Rica, Costa Rica
- Leticia Caligaris, Uruguay
- Catalina Cano Abásolo, Head of the Department of Pharmaceutical Policies and Regulations, Health Providers and Complementary Medicines.
Division of Healthy Public Policies and Promotion Assistant Secretary of Public Health, Ministry of Health, Chile
- Timothy Aungst, Associate Professor. Freelance Writer and Consultant The Digital Apothecary, USA

Changes in climate constitute a reality that, according to recent projections, is going to worsen in the coming years.1 Increasing air pollution and climate change have an impact on respiratory health and mortality where climate change represents a massive direct threat to respiratory health by promoting or aggravating respiratory diseases or indirectly by increasing exposure to risk factors for respiratory diseases.

Overall Aim:
To support pharmacists to play a proactive role in respiratory management of the health impact of indoor air pollution by helping to address their practice and education needs to enable them to provide better patient advice and self-care.

Learning objectives:

- Identify the changes in climate as well as the interrelationship between climate change and air pollution
- Understand the impact of climate change and air pollution on health particularly respiratory health
- Understand how climate change and air pollution affect people living in low- and middle-income countries
- Know the intervention, treatment and management strategies including self-care measures to minimize the impact on respiratory health
- Recognize the role pharmacists must play to support better health care delivery and patient care

Moderator:
- Gonçalo  Sousa Pinto, Lead for practice development and transformation, FIP Spain

Panelsists:
- Kian Fan Chung, Professor of Respiratory Medicine, National Heart & Lung Institute, Imperial College London, United Kingdom
- Sundeep Salvi, Founder and Director The Chest Research Foundation, India
- Lina Bader, FIP Lead for Equity, sustainability policy and development International Pharmaceutical Federation (FIP), Saudi Arabia
- Ravijyot Saggu, Lead clinical pharmacist and CPhO clinical fellow ’21/’22, NHS England, UK

Influenza and COVID-19 can have an important impact in health, productivity and quality of life, especially for vulnerable populations. Likewise, both diseases have vaccines that are available and support a lower risk of transmission of the disease.

Pharmacists can play a major role in reminding people to get vaccinated, building vaccine confidence and supporting their decision making, dispensing vaccines and, in some countries, administering those vaccines.  The coadministration of these vaccines can lead to an efficient and convenient way of improving vaccine uptake against both diseases. Community pharmacies’s accessibility and credibility put them in an ideal situation to provide this important service, thus making a valuable contribution to disease prevention.

This digital event will discuss the importance of promoting the coadministration of COVID-19 and flu vaccines as well as strategies for pharmacies’ involvement.

By the end of the session participants should be able to:

• Understand the benefits of vaccine coadministration
• Recognize the need for vaccination coverage in both flu and COVID-19
• Present the FIP Guideline on this topic

Moderator:

- Daragh Connolly, President, Community Pharmacy Section, Ireland

Panellist:

- Mitchel Rothholz, Immunization Consultant, Three-C Consulting, USA
- Lisa Nissen, Professor (Program Director) – Health Workforce Optimisation, Centre for Business and Economics of Health, (Faculty of Business), Australia
- Sham Moodley, Pharmacist, Pharmaceutical Society of South Africa/Independent Community Pharmacy Assoc (ICPA), South Africa
- Paula Teixeira, Scientific Information Manager, Center for Medicines Information and Health Interventions (CEDIME) in the Portuguese National Association of Pharmacies (ANF), Portugal
- Rúben Viegas, FIP Practice Development and Transformation Projects Coordinator, Portugal

Substandard and falsified medicines, along with a lack of adherence to medication regimens, pose a threat to public health worldwide. It is possible to deliver pharmaceutical care services that address these challenges using digital healthcare techniques and approaches. Globally, digital health faces many challenges and concerns, despite its potential to impact pharmaceutical care.

FIP and the Global Pharmaceutical Observatory are launching a new needs assessment programme entitled "How can digital health support national pharmaceutical care delivery? A regional and global assessment of priorities and challenges", with an emphasis on medication adherence and fighting SF medicines.

This regional and global needs assessment programme will include a series of six regional events, culminating in a private global roundtable and a summary report.

In this regional event we will facilitate a regional discussion about ongoing digital health interventions or solutions that detect, report, and act against false or substandard medicines, and how to facilitate patient adherence, as well as the challenges leadership bodies and nations face in implementing digital health solutions in pharmaceutical care delivery in South East Asia.

Moderator:
-Tanniru V Narayana, President SEARPharm Forum, India

Panelists:
-Rao Vadlamudi, Professional Secretary/Immediate past president SEARPharm Forum/ the Indian Pharmaceutical Association, India
-Hilwan Yuda Teruna, Vice President Indonesian Pharmacist Association, Indonesia
-Kelum Jayasuriya, Group Manager Pharmacy Operations Asiri Group of Hospitals, Sri Lanka
-Chinta Abayawardana, Past President, Pharmaceutical Society of Sri Lanka, Sri Lanka

Substandard and falsified medicines, along with a lack of adherence to medication regimens, pose a threat to public health worldwide. It is possible to deliver pharmaceutical care services that address these challenges using digital healthcare techniques and approaches. Globally, digital health faces many challenges and concerns, despite its potential to impact pharmaceutical care.
FIP and the Global Pharmaceutical Observatory are launching a new needs assessment programme entitled "How can digital health support national pharmaceutical care delivery? A regional and global assessment of priorities and challenges", with an emphasis on medication adherence and fighting SF medicines.
This regional and global needs assessment programme will include a series of six regional events, culminating in a private global roundtable and a summary report.

Aim:
Facilitate a regional discussion about ongoing digital health interventions or solutions that detect, report, and act against false or substandard medicines, and how to facilitate patient adherence, as well as the challenges leadership bodies and nations face in implementing digital health solutions in pharmaceutical care delivery in Europe

This event will focus on pharmacists’ roles in influenza prevention through vaccination and increasing influenza vaccination coverage rate. The event will focus on the risks of influenza and showcase good practices from pharmacists across the continent on pharmacists’ public health role through influenza vaccination, digital health solutions in pharmacy on influenza vaccination and effective communication with patients to deliver flu vaccines on the right time. This event aims to improve pharmacists' knowledge, improve pharmaceutical services delivery and overall health outcomes of the public in the context of influenza vaccination.

Learning objectives:
1. Improve knowledge of pharmacists on the risks of influenza
2. Exploring pharmacists’ roles in influenza prevention through vaccination and increasing influenza vaccination coverage rate within the African region;
3. Showcase country cases from pharmacists across the continent on influenza vaccination, digital vaccination solutions and patient communication on vaccines.

Moderator:
- Arinola Joda, Assistant Secretary and Editor-in- Chief, African Pharmaceutical Forum, Faculty of Pharmacy, University of Lagos, Nigeria

Guests:
- Cheryl Cohen, Professor & Head Centre for Respiratory Disease and Meningitis, National Institute for Communicable Diseases and School of Public Health, University of the Witwatersrand, Johannesburg, South Africa, South Africa
- Gonçalo  Sousa Pinto, Lead for practice development and transformation, FIP, Portugal
- Redouane Soualmi, Chairperson of external relations Algerian Pharmaceutical Federation - Fédération Algérienne de Pharmacie, Algeria
- Merilynn Steenkamp, General Manager Sanofi Vaccines, South Africa
- Wael Ali, General Secretary, EMRPharm Forum , President Egyptian organization of pharmacy, Egypt

Facilitators:
- Nilhan Uzman, Lead for Education and Primary Health Policies, FIP, Turkey
- Alison Etukakpan, Educational Partnership Specialist, FIP, Nigeria

This event will focus on pharmacists’ roles in influenza prevention through vaccination and increasing influenza vaccination coverage rate. The event will focus on the risks of influenza and showcase good practices from pharmacists across the continent on pharmacists’ public health role through influenza vaccination, digital health solutions in pharmacy on influenza vaccination and effective communication with patients to deliver flu vaccines on the right time. This event aims to improve pharmacists' knowledge, improve pharmaceutical services delivery and overall health outcomes of the public in the context of influenza vaccination.

Learning objectives:
1. Improve knowledge of pharmacists on the risks of influenza
2. Exploring pharmacists’ roles in influenza prevention through vaccination and increasing influenza vaccination coverage rate within the African region;
3. Showcase country cases from pharmacists across the continent on influenza vaccination, digital vaccination solutions and patient communication on vaccines.

Moderator:
- Arinola Joda, Assistant Secretary and Editor-in- Chief, African Pharmaceutical Forum, Faculty of Pharmacy, University of Lagos, Nigeria

Guests:
- Cheryl Cohen, Professor & Head Centre for Respiratory Disease and Meningitis, National Institute for Communicable Diseases and School of Public Health, University of the Witwatersrand, Johannesburg, South Africa, South Africa
- Gonçalo  Sousa Pinto, Lead for practice development and transformation, FIP, Portugal
- Redouane Soualmi, Chairperson of external relations Algerian Pharmaceutical Federation - Fédération Algérienne de Pharmacie, Algeria
- Merilynn Steenkamp, General Manager Sanofi Vaccines, South Africa
- Wael Ali, General Secretary, EMRPharm Forum , President Egyptian organization of pharmacy, Egypt

Facilitators:
- Nilhan Uzman, Lead for Education and Primary Health Policies, FIP, Turkey
- Alison Etukakpan, Educational Partnership Specialist, FIP, Nigeria

This will be a 2-part workshop to introduce the FIP YPG Career Development toolkit. Part 1 will review the toolkit, the available resources, and discuss how it will benefit the user. Attendees will then be instructed to work through the toolkit over the next few weeks.

Part 2 of the workshop will be an engaging session where participants are asked to return with their completed toolkits to discuss what they learned with other attendees, review their toolkits in breakout rooms, and have the opportunity to ask questions.

Facilitar el acceso a los medicamentos: Bioequivalencia - Metodologías In Vitro para la Demostración de Equivalencia Terapéutica

Sesión VI: Metodología GA-RxODE en ensayos clínicos de Bioequivalencia Fundamentos y aplicaciones.

Sesión en Español.

Este webinar tiene como objetivo presentar los siguientes conceptos:

• Definiciones e hipótesis de trabajo;
• Fundamentos de la metodología GA-RxODE;
• Aplicaciones farmacométricas y en particular Beq;
• Resultados obtenidos;
• Limitaciones del modelo y conclusiones.

Moderadora:
Talita Ferreira, MsC Coordinadora de Proyectos de bioequivalencia en Latinoamérica International Pharmaceutical Federation (FIP)-Brasil

Panelisto:
Dr. Héctor Alejandro Serra, Profesor Departamento de Farmacología; Facultad de Medicina; Universidad de Buenos Aires-Argentina

Facilitar el acceso a los medicamentos: Bioequivalencia - Metodologías In Vitro para la Demostración de Equivalencia Terapéutica

Sesión V: Bioequivalencia - Estudios de Permeabilidad: principios, metodologías y análisis de datos

Sesión en Español

Este webinar tiene como objetivo presentar los conceptos:

• Rutas de absorción oral de fármacos
• Transportadores intestinales
• Estudios de permeabilidad in vitro
• Impacto de excipientes sobre la absorción oral de fármacos
• Aplicaciones de los estudios de permeabilidad

Moderadora:
-Talita Ferreira, FIP Coordinadora de Proyectos de bioexención en Latinoamérica, Brasil

Panelista:
-Pablo González, CEO Innovation and Biopharmaceutical Evaluation Center-Chile

Pharmacy needs to build sustained data and analytics capabilities that support evidence-based decision making and advocacy interventions that inform policy development. Improving capacity in data and intelligence across FIP and its member organisations, is essential to advance pharmacy world-wide. This event explores challenges and opportunities that maximise the use of data to generate evidence of impact across safe and effective use of medicines, pharmacy practice and the pharmacy workforce..

Aim
To describe approaches for delivering the required data and intelligence to generate evidence of impact for the profession and current and future policy: enablers and barriers that will support this through practical approaches.

Learning objectives:

1) Explain how health information systems can be strengthened;
2) Describe approaches to evidence generation;
3) List current enablers/opportunities and barriers for using pharmacy data and intelligence to their full potential;
4) Discuss how the pharmacy profession makes better use of data and intelligence.

Moderator:
- Christopher John, FIP Lead for Data and Intelligence FIP, UK

Panellists:
- Sallie Pearson, Professor of Health Systems Research UNSW Sydney, Australia
- Astrid Czock, FIP Global Lead for DG8: Working with others, CEO Qauliccare, Switzerland
- Saja A. Alnahar, Assistant Professor Yarmouk University, Jordan
- Hong Anh Chu, Technical Officer, WHO, Switzerland

Vaccination is one of the most effective measures to prevent disease transmission and protect populations from a variety of diseases that heavily impact individuals and health systems. Overall, through the provision of person-centred pharmaceutical services, pharmacists play a key role ensuring healthy lives and promoting wellbeing, as well as promoting more effective, rational, and widespread use of vaccines. Among the different special-risk population groups for vaccine-preventable diseases, people living with cardiovascular diseases have particular vaccination needs that will be highlighted at this event.

Learning objectives:
By the end of the session participants should be able to:
• Understand the risks that this particular population group is exposed to with regards to vaccine-preventable diseases, as well as the benefits of being vaccinated
• Understand the main recommended vaccines for people living with cardiovascular diseases
• Discuss the role of pharmacists in supporting health literacy and vaccination of this special risk group

Moderator:
- Renly Lim, FIP YPG Immediate Past President, Research Fellow University of South Australia, Australia

Panellists:
- Alvaro Sosa Liprandi, President Interamerican Society of Cardiology, Argentina
- Tolulope Osigbesan, Senior Policy and Advocacy Officer NCD Alliance, Switzerland
- John D. Grabenstein, RPh, PhD, Director of Scientific Communications Immunize.org, USA

Vaccination is one of the most effective measures to prevent disease transmission and protect populations from a variety of diseases that heavily impact individuals and health systems. Overall, through the provision of person-centred pharmaceutical services, pharmacists play a key role ensuring healthy lives and promoting wellbeing, as well as promoting more effective, rational, and widespread use of vaccines. Among the different special-risk population groups for vaccine-preventable diseases, people living with cardiovascular diseases have particular vaccination needs that will be highlighted at this event.

Learning objectives:
By the end of the session participants should be able to:
• Understand the risks that this particular population group is exposed to with regards to vaccine-preventable diseases, as well as the benefits of being vaccinated
• Understand the main recommended vaccines for people living with cardiovascular diseases
• Discuss the role of pharmacists in supporting health literacy and vaccination of this special risk group

Moderator:
- Renly Lim, FIP YPG Immediate Past President, Research Fellow University of South Australia, Australia

Panellists:
- Alvaro Sosa Liprandi, President Interamerican Society of Cardiology, Argentina
- Tolulope Osigbesan, Senior Policy and Advocacy Officer NCD Alliance, Switzerland
- John D. Grabenstein, RPh, PhD, Director of Scientific Communications Immunize.org, USA

Several factors can influence digestive wellness and gut wellness, including stress, nutrition or medication. Disruptions to the microbiota homeostasis can lead to gastrointestinal symptoms and have an impact in immunity. This event will discuss dysbiosis and the role that pharmacists can have in improving gut wellness and immunity.

By the end of the session participants should be able to:
• Understand dysbiosis and gut wellness
• Identify tips to manage abdominal pain
• Understand the role of diet in immunologic modulation
• Understand the use of probiotics for gut wellness

Moderator:
- Bidhata Khatri, FIP Health and Medicines Information Section (HaMIS) Secretary FIP, India

Panelists:
- Saman Khalesi, Senior Lecturer and Discipline Lead – Nutrition Central Queensland University (CQUniversity); Postdoctoral Fellow of the National Heart Foundation of Australia, Australia
- Ana Faria, Assistant Professor Nova Medical School - Universidade Nova de Lisboa, Portugal
- Ender Pehlivanoglu, Professor of Pediatric Gastroeneterology&Nutrition Istanbul Kent University, Turkey
- Metehan Özen, Pediatric Infectious Disease Specialist Acibadem University, School of Medicine, Turkey

Several factors can influence digestive wellness and gut wellness, including stress, nutrition or medication. Disruptions to the microbiota homeostasis can lead to gastrointestinal symptoms and have an impact in immunity. This event will discuss dysbiosis and the role that pharmacists can have in improving gut wellness and immunity.

By the end of the session participants should be able to:
• Understand dysbiosis and gut wellness
• Identify tips to manage abdominal pain
• Understand the role of diet in immunologic modulation
• Understand the use of probiotics for gut wellness

Moderator:
- Bidhata Khatri, FIP Health and Medicines Information Section (HaMIS) Secretary FIP, India

Panelists:
- Saman Khalesi, Senior Lecturer and Discipline Lead – Nutrition Central Queensland University (CQUniversity); Postdoctoral Fellow of the National Heart Foundation of Australia, Australia
- Ana Faria, Assistant Professor Nova Medical School - Universidade Nova de Lisboa, Portugal
- Ender Pehlivanoglu, Professor of Pediatric Gastroeneterology&Nutrition Istanbul Kent University, Turkey
- Metehan Özen, Pediatric Infectious Disease Specialist Acibadem University, School of Medicine, Turkey

Several factors can influence digestive wellness and gut wellness, including stress, nutrition or medication. Disruptions to the microbiota homeostasis can lead to gastrointestinal symptoms and have an impact in immunity. This event will discuss dysbiosis and the role that pharmacists can have in improving gut wellness and immunity.

By the end of the session participants should be able to:
• Understand dysbiosis and gut wellness
• Identify tips to manage abdominal pain
• Understand the role of diet in immunologic modulation
• Understand the use of probiotics for gut wellness

Moderator:
- Bidhata Khatri, FIP Health and Medicines Information Section (HaMIS) Secretary FIP, India

Panelists:
- Saman Khalesi, Senior Lecturer and Discipline Lead – Nutrition Central Queensland University (CQUniversity); Postdoctoral Fellow of the National Heart Foundation of Australia, Australia
- Ana Faria, Assistant Professor Nova Medical School - Universidade Nova de Lisboa, Portugal
- Ender Pehlivanoglu, Professor of Pediatric Gastroeneterology&Nutrition Istanbul Kent University, Turkey
- Metehan Özen, Pediatric Infectious Disease Specialist Acibadem University, School of Medicine, Turkey

This event will showcase how nations have coordinated pharmacy support for person-centred care in the fight against COVID-19 with a focus on strategy, policy and practice. Barriers and enablers to pharmacy’s involvement in the pandemic will be discussed as well as insights for countries wanting to advocate for pharmacy’s greater contribution in health systems. The future role of pharmacy in pandemics will be highlighted.

Aim
To describe current and future pharmacy practice in delivering person-centred care during the fight against COVID-19 and possible future pandemics.

Learning objectives:

1. List policy and professional enablers and barriers for developing pharmacy practice during the COVID-19 pandemic;
2. Give examples of pharmacy services used in the fight against COVID-19;
3. Describe approaches for advocating for pharmacy support in pandemics;
4. Predict the role of the pharmacist and their teams in future pandemics.

Moderators:
-Nadia Bukari, FIP Global Lead/Associate Professor, University College London FIP/UCL, UK
-Abby Kahaleh, PhD, MS, BPharm, MPH, FAACP, FIP Global Lead on Quality Assurance for Pharmacy Education, Tenured Associate Professor for Clinical and Administrative Sciences; Board of Trustees Faculty, Roosevelt University, USA

Panelsits:
-Suzete Costa, PharmD, MPH, PhD Executive Director & Senior Research Director Institute for Evidence-Based Health (ISBE), Portugal
-Michael Ganio, Senior Director, Pharmacy Practice and Quality ASHP, USA
-Shepard Mhlaba, FIP Global Lead, FIP Workforce Development Hub, WDG2: Early career training strategy, Drug Information Pharmacist/Research Assistant, Drug and Toxicology Information Services (DATIS), Harare, Zimbabwe

Irritable bowel syndrome (IBS) is a common chronic gastrointestinal disorder that affects people of all ages. Pharmacists can play an important role in symptom management, referral to other healthcare professionals and provision of advice to improve quality of life. This event will provide an overview of the main roles pharmacists can have in supporting people living with IBS, from a community pharmacy perspective.

By the end of the session participants should be able to:
• Discuss the role of community pharmacists around IBS
• Understand the difference in symptoms between abdominal cramping pain and IBS
• Identify red flag symptoms for referral of IBS patients

Facilitar el acceso a los medicamentos: Bioequivalencia - Metodologías In Vitro para la Demostración de Equivalencia Terapéutica

Sesión IV: Bioequivalencia - Estudios de Disolución de Formas Farmacéuticas

Sesión en Español

 Este webinar tiene como objetivo presentar los conceptos:

• Aspectos teóricos de la disolución de APIs

o   Etapas

o   Modelos

• Disolutores

o   Aparatos I-IV y aplicaciones

• Aplicaciones de los Estudios de disolución comparativa
• Metodologías de disolución con cambio de pH
• Medios biorrelevantes y bicarbonato

Moderadora:
- Talita Ferreira, FIP Coordinadora de Proyectos de bioexención en Latinoamérica, Brasil

Panelista:
- Pablo González, CEO Innovation and Biopharmaceutical Evaluation Center, Chile

Consumers throughout the world are increasingly looking to the internet to purchase their drugs. The worldwide pandemic has caused many consumers, who had not done so previously, to look to the internet for healthcare, healthcare information and medicinal products. However, at any given time, 95% of the roughly 35,000 online drug sellers worldwide operate illegally, in violation of laws and placing consumers at risk. Drugs purchased through an illegal drug seller on the internet may contain no drug, subtherapeutic levels of a drug, a completely different drug, or toxic chemicals. These websites will appear to be “pharmacies” or other “medical centres” providing credible health care, drug information and safe and approved medications, but are not and present risk to the unknowing consumer.

Regulators throughout the world are monitoring the level of nefarious drug sellers and “medical clinics” on the internet. Regulatory solutions to combat and remove the presence of these harmful vendors and sites have not been widely implemented. Public awareness is an important step, but also raising the awareness among healthcare providers, law makers and social media platforms.

Learning Objectives:
-To identify the level of illegal online drug sellers and bogus medical clinics on the internet and impact on the unsuspecting public
-To identify the barriers to overcome and better protect the public.
To identify programs and initiatives currently in place to combat misinformation, poor virtual care and falsified medication to enhance the safety and protect the internet consumer
-To encourage and support standards for virtual care.

Moderator:
-Ronald Guse, Chair FIP Regulators Forum - Canada
Panelists:
-Mike Isles,Director Alliance for Safe Online Pharmacy-EU-UK
-Justin Macy,Digital Health Senior Manager National Association of Boards of Pharmacy-USA
-Libby Baney,Senior Advisor to ASOP Global; Partner, Faegre Drinker LLP, Alliance for Safe on Pharmacy Global-USA

Overall Aim:
To support pharmacists to play a proactive role in respiratory management of the health impact of indoor air pollution by helping to address their practice and education needs to enable them provide better patient advice and self-care.

Learning objectives:
• Identify the sources of indoor air pollution and its increasing threat to health
• Understand the short- and long-term impact of indoor air pollution particularly on children
• Understand clinical, pharmacological, and non-pharmacological treatments including self-care measures to minimize the impact of air pollution on respiratory health
• Illustrate how advocacy can impact behavior change to support adoption of better self-care practices aimed at reducing health impact of air pollution.

Moderator:
- Lina Bader, FIP Lead for Equity, sustainability policy and development International Pharmaceutical Federation, Saudi Arabia

Facilitator:
- Nour Eltahla, FIP Projects Coordinator for Equity, sustainability policy and development International Pharmaceutical Federation, Saudi Arabia

Panelists:
- Lidia Morawska, Director International Laboratory for Air Quality and Health (WHO CC for Air Quality and Health), Queensland University of Technology, Australia
- Gary WK Wong, Professor and honorary consultant, Department of Paediatrics, Chinese University of Hong Kong, Hong Kong
- Tyler Knowlton, Director of Communications, Communities, and Partnerships Plume Labs, France

The demand for travel health and travel medicine services is rapidly growing with the return levels of international travel. Patients are frequently turning to community pharmacies for advice on disease reduction and maintaining personal health whilst travelling. Pretravel preparation is important for many reasons one of which is supporting Global Health policies and strategies.

In some countries legislation has been devolved to allow pharmacists to prescribe medication and vaccinate travellers. However, this is not the situation globally and the many countries place restrictions on this type of pharmacy practice.

Learning objectives:
- To raise the awareness of pretravel consultation service that can be provided in a community setting without prescribing or vaccination.
- To identify over-the-counter products that can be supplied to support travellers visiting a pharmacy
- Compare and contrast classes of over-the-counter products for selected conditions and identify/select appropriate patients for their use.
- Showcase the collaborations with the International Institute of Travel Medicine through membership of ISTM and completion of Certificate of Health

Moderator:
- Daragh Connolly, President Community Pharmacy Section, Ireland

Panelists:
- Derek Evans, Pharmacist Specialist in Travel Medicine Evans Travel Health consultancy, UK
- Karl Hess, Director, Community Pharmacy Practice Innovations Department of Pharmacy Practice, Chapman University School of Pharmacy, Irvine, California, USA
- Sheila Seed, Professor and Chair of Pharmacy Practice, Massachusetts College of Pharmacy and Health Sciences, USA
- Larry Goodyer, Professor of Pharmacy Practice, Leicester School of Pharmacy Faculty of Health and Life Sciences, De Montfort University, UK

The importance of good mental health and wellbeing has gained attention over the last decade due to an increased burden of disability and loss of quality of life associated with mental health conditions. Pharmacists have a significant role in the support and management of persons with mental health illnesses and in reducing the commonly associated stigma. FIP has developed a new handbook to support pharmacists and their organisations in providing a range of mental health-related services. In addition, the handbook will be accompanied by the knowledge and skills (K&S) reference guide in mental health which identifies the K&S that pharmacists require for the provision of such services, thus offering guidance to pharmacists, academic institutions and CPD providers. Both publications will be launched at this event and they are part of the FIP Practice Transformation Programme on Non-Communicable Diseases.

Attendees will learn about:

1. The role of pharmacists in the prevention, identification, care and management of mental health illnesses;
2. Challenges and opportunities for pharmacists in addressing mental health illnesses;
3. The knowledge and skills pharmacists need to acquire to support their role in mental health.

Moderator:
- Inês Nunes da Cunha, FIP Practice Development and Transformation Projects Manager, Portugal

Panelsits:
- Claire O’Reilly, Senior Lecturer School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Australia
- Sarira El-Den, Senior Lecturer The University of Sydney School of Pharmacy, Australia
- Jiahui (Jeff) Dong, PharmD Candidate The University of North Carolina, Eshelman School of Pharmacy, United States
- Dalia Bajis, FIP Lead for provision and partnerships, Australia

The Universal Health Coverage (UHC) Competency Framework was published by WHO as a guide to progress towards building more holistic and integrated health systems. Critically, this includes human resources education and the implementation of Competency-Based Education (CBE) for healthcare workers to ensure adequate, and integrated, education and training.

WHO Universal Health Coverage Competency Framework: https://www.who.int/publications/i/item/9789240034686

Learning Objectives:

1. Overview of the principles and objectives of the WHO universal health coverage competency framework
2. Understand competency-based education and its role in developing the global healthcare workforce for UHC
3. Contextualize the UHC competency development guide to fulfil training needs - based on country of practice
4. Focus on pharmacy and pharmacy support workforce role in UHC

Moderator:
- Abigail Tan Ming Li, Staff training and the planning of continuing education topics. KK Women's and Children's Hospital, Singapore

Panelists:
- Ian Bates, Director of the FIP Global Pharmaceutical Observatory, Chair of pharmacy education University College London, United Kingdom
- Siobhan Fitzpatrick, WHO technical officer WHO, Switzerland

This first event in the FIP 2022 series 'Food for thought: Pharmacists' role in health nutrition' aims to describe the basics of nutrition for pharmacists, and the role of pharmacists in providing nutrition services for better health outcomes, expanding from the 2021 FIP report "Nutrition and weight management services: A toolkit for pharmacists".

Moderator:
- Jaime Acosta, Community Pharmacist, Farmacia Acosta, Spain

Panellists:
- Joanna Harnett, Senior Lecturer, Sydney Pharmacy School, Australia
- Rúben Viegas, Practice Development Projects Coordinator, FIP, Portugal

Vaccination is one of the most effective measures to prevent disease transmission and protect populations from a variety of diseases that heavily impact individuals and health systems. Overall, through the provision of person-centred pharmaceutical services, pharmacists play a key role ensuring healthy lives and promoting wellbeing, as well as promoting more effective, rational, and widespread use of vaccines. Among the different special-risk population groups, people living with chronic respiratory conditions have specific vaccination needs that will be discussed in this event.

By the end of the session participants should be able to:

-Understand the risks that this particular population group is exposed to with regards to vaccine-preventable diseases, as well as the benefits of being vaccinated
-Understand the main recommended vaccines for people living with chronic respiratory diseases
-Discuss the role of pharmacists in supporting health literacy and vaccination of this special risk group

Moderator:
-Peter Guthrey, Executive Committee Member of the Social and Administrative Pharmacy Section of FIP; Senior pharmacists - strategic policy The Pharmaceutical Society of Australia - Australia 

Panelists:
-Ema Paulino,  President  National Association of Pharmacies, Portugal (ANF), Portugal
-Fiona Mosgrove, General Practitioner NHS Grampian, UK
-Carmen Baldonedo Mosteiro, Community Pharmacist. Member of the Respiratory task force of the Spanish Society of community Pharmacy (SEFAC), Spanish society of clinical, familiar and community Pharmacy (SEFAC), Spain

Vaccination is one of the most effective measures to prevent disease transmission and protect populations from a variety of diseases that heavily impact individuals and health systems. Overall, through the provision of person-centred pharmaceutical services, pharmacists play a key role ensuring healthy lives and promoting wellbeing, as well as promoting more effective, rational, and widespread use of vaccines. Among the different special-risk population groups, people living with chronic respiratory conditions have specific vaccination needs that will be discussed in this event.

By the end of the session participants should be able to:

-Understand the risks that this particular population group is exposed to with regards to vaccine-preventable diseases, as well as the benefits of being vaccinated
-Understand the main recommended vaccines for people living with chronic respiratory diseases
-Discuss the role of pharmacists in supporting health literacy and vaccination of this special risk group

Moderator:
-Peter Guthrey, Executive Committee Member of the Social and Administrative Pharmacy Section of FIP; Senior pharmacists - strategic policy The Pharmaceutical Society of Australia - Australia 

Panelists:
-Ema Paulino,  President  National Association of Pharmacies, Portugal (ANF), Portugal
-Fiona Mosgrove, General Practitioner NHS Grampian, UK
-Carmen Baldonedo Mosteiro, Community Pharmacist. Member of the Respiratory task force of the Spanish Society of community Pharmacy (SEFAC), Spanish society of clinical, familiar and community Pharmacy (SEFAC), Spain

Facilitar el acceso a los medicamentos: Bioequivalencia - Metodologías In Vitro para la Demostración de Equivalencia Terapéutica

Sesión III: Bioequivalencia - Estudios de Solubilidad de Fármacos

Sesión en Español

Este webinar tiene como objetivo presentar los conceptos:

• Factores del API que determinan su solubilidad
• Factores del medio que determinan la solubilidad del API
• Metodologías

o   Método termodinámico

o   Método cinético

• Modificación tecnológica de la solubilidad de API

Moderadora:
-Talita Ferreira, FIP Coordinadora de Proyectos de bioexención en Latinoamérica, Brasil

Panelista:
-Pablo González, CEO Innovation and Biopharmaceutical Evaluation Center, Chile

Substandard and falsified medicines, along with a lack of adherence to medication regimens, pose a threat to public health worldwide. It is possible to deliver pharmaceutical care services that address these challenges using digital healthcare techniques and approaches. Globally, digital health faces many challenges and concerns, despite its potential to impact pharmaceutical care.

 FIP and the Global Pharmaceutical Observatory are launching a new needs assessment programme entitled "How can digital health support national pharmaceutical care delivery? A regional and global assessment of priorities and challenges", with an emphasis on medication adherence and fighting SF medicines.

This regional and global needs assessment programme will include a series of six regional events, culminating in a private global roundtable and a summary report.

In this regional event we will facilitate a regional discussion about ongoing digital health interventions or solutions that detect, report, and act against false or substandard medicines, and how to facilitate patient adherence, as well as the challenges leadership bodies and nations face in implementing digital health solutions in pharmaceutical care delivery in the EMR.

Moderator:

- Samira Shammas, Bureau Liaison - EMR, FIP, Jordan

Co-Moderator & Facilitators :

- Meshkat Torkamanian, FIP - YPG Early Career Regional Supporter, Iran
- Farah Aqqad, FIP Regional Engagement, Support and Development Manager, Jordan
- Hamsa Hassan, FIP - YPG Early Career Regional Supporter, Egypt

Panellists:

- Akbar Abdollahiasl, Assistant Professor, Department of Pharmacoeconomics and Pharmaceutical Administration, Faculty of Pharmacy, Tehran University of Medical Sciences, Iran
- Saleh Hanash, Pharmapreneur/Founder of Agonist Consult, Agonist Consult, Jordan
- Ali Omeiat, Head of pharmacies and drug stores inspection section, Inspection and control department, Jordan Food & Drug Administration, Jordan
- Ahmed Hamdan Aljedai, Assistant Deputy Minister for Medical support Services, Ministry of Health, Saudi Arabia

This event will discuss pharmacists’ roles in diabetes prevention, screening and management by showcasing best practices in pharmaceutical care, identifying needs and priorities of pharmacists, digital health applications, new trends and practices across Africa. According to WHO, diabetes in the region is a serious, chronic, and costly disease that is estimated to rise to 23.9 million cases by 2030, and up to 15% of adults aged 25 to 64 have diabetes in the African region. s. Pharmacists are uniquely positioned to provide a wide array of services to prevent, identify and manage both type 1 and type 2 diabetes as well as support the care provided by other members of the healthcare team. This event aims to improve pharmacists' knowledge, improve pharmaceutical services delivery and overall health outcomes of the public in the context of diabetes.

Learning objectives:

• Improve knowledge of pharmacists by exploring the role of pharmacists in the prevention, screening and management of diabetes within the African region;
• Showcase emerging digital health trends, new applications for patients and innovative pharmaceutical services delivery for diabetes within the African region;
• Identify the needs and priorities of pharmacists in the prevention and management of diabetes within the African region.

Moderator:
- Prosper Hiag, President African Pharmaceutical Forum, Cameroon

Guests:
- Danielle Munene, Head of Consulting African Health Business, Kenya
- Imraan Bismilla, Head of Pharmacy Centre for Diabetes and Endocrinology in South Africa, South Africa
- Mohamed Yacine Achouri, President of the scientific communication Fédération Algérienne de Pharmacie, Algeria
- Khadir Sarra, Pharmacy resident, FIP YPG remote intern, Algeria
- Gonçalo Sousa Pinto, FIP Lead for practice development and transformation, Spain

Facilitators:
-Nilhan Uzman, Lead for Education and Primary Health Policies FIP, Turkey
-Alison Etukakpan, Educational Partnership Specialist International Pharmaceutical Federation, Nigeria

This event will discuss pharmacists’ roles in diabetes prevention, screening and management by showcasing best practices in pharmaceutical care, identifying needs and priorities of pharmacists, digital health applications, new trends and practices across Africa. According to WHO, diabetes in the region is a serious, chronic, and costly disease that is estimated to rise to 23.9 million cases by 2030, and up to 15% of adults aged 25 to 64 have diabetes in the African region. s. Pharmacists are uniquely positioned to provide a wide array of services to prevent, identify and manage both type 1 and type 2 diabetes as well as support the care provided by other members of the healthcare team. This event aims to improve pharmacists' knowledge, improve pharmaceutical services delivery and overall health outcomes of the public in the context of diabetes.

Learning objectives:

• Improve knowledge of pharmacists by exploring the role of pharmacists in the prevention, screening and management of diabetes within the African region;
• Showcase emerging digital health trends, new applications for patients and innovative pharmaceutical services delivery for diabetes within the African region;
• Identify the needs and priorities of pharmacists in the prevention and management of diabetes within the African region.

Moderator:
- Prosper Hiag, President African Pharmaceutical Forum, Cameroon

Guests:
- Danielle Munene, Head of Consulting African Health Business, Kenya
- Imraan Bismilla, Head of Pharmacy Centre for Diabetes and Endocrinology in South Africa, South Africa
- Mohamed Yacine Achouri, President of the scientific communication Fédération Algérienne de Pharmacie, Algeria
- Khadir Sarra, Pharmacy resident, FIP YPG remote intern, Algeria
- Gonçalo Sousa Pinto, FIP Lead for practice development and transformation, Spain

Delayed access cost lives. Many low- and middle-income countries lack the regulatory tools for timely access to medical products for unmet public health needs. The current COVID-19 pandemic has shown that it is important to have available regulatory flexibilities to authorize new medical products for use and rapidly manufactured them at scale. Expedited regulatory pathways (ERP) can help countries to accelerate the approval and access to new medical products with positive benefit-risk balance. To best meet those objectives of ERP, developing countries require strong reliance practices and post-authorization surveillance systems as pre-requisite for the timely introduction and safe use of new medical products for unmet public health needs and health emergencies.

Learning Objectives:
1) How regulatory flexibility in low and middle- income countries makes it possible to get expedited drug approvals
2) Why post- authorization surveillance is necessary to enable safe introduction of drugs approved by expedited pathway

Moderators:
- Mathew Cherian, PhD Consultant, FIP Member, Executive Committee, Industrial Pharmacy Section, USA
- Maria Mantziri, Associate ExCo Member, IPS Webinars, Greece

Panelist:
- Jude Nwokike, Vice- President US Pharmacopeia, USA

Delayed access cost lives. Many low- and middle-income countries lack the regulatory tools for timely access to medical products for unmet public health needs. The current COVID-19 pandemic has shown that it is important to have available regulatory flexibilities to authorize new medical products for use and rapidly manufactured them at scale. Expedited regulatory pathways (ERP) can help countries to accelerate the approval and access to new medical products with positive benefit-risk balance. To best meet those objectives of ERP, developing countries require strong reliance practices and post-authorization surveillance systems as pre-requisite for the timely introduction and safe use of new medical products for unmet public health needs and health emergencies.

Learning Objectives:
1) How regulatory flexibility in low and middle- income countries makes it possible to get expedited drug approvals
2) Why post- authorization surveillance is necessary to enable safe introduction of drugs approved by expedited pathway

Moderators:
- Mathew Cherian, PhD Consultant, FIP Member, Executive Committee, Industrial Pharmacy Section, USA
- Maria Mantziri, Associate ExCo Member, IPS Webinars, Greece

Panelist:
- Jude Nwokike, Vice- President US Pharmacopeia, USA

Delayed access cost lives. Many low- and middle-income countries lack the regulatory tools for timely access to medical products for unmet public health needs. The current COVID-19 pandemic has shown that it is important to have available regulatory flexibilities to authorize new medical products for use and rapidly manufactured them at scale. Expedited regulatory pathways (ERP) can help countries to accelerate the approval and access to new medical products with positive benefit-risk balance. To best meet those objectives of ERP, developing countries require strong reliance practices and post-authorization surveillance systems as pre-requisite for the timely introduction and safe use of new medical products for unmet public health needs and health emergencies.

Learning Objectives:
1) How regulatory flexibility in low and middle- income countries makes it possible to get expedited drug approvals
2) Why post- authorization surveillance is necessary to enable safe introduction of drugs approved by expedited pathway

Moderators:
- Mathew Cherian, PhD Consultant, FIP Member, Executive Committee, Industrial Pharmacy Section, USA
- Maria Mantziri, Associate ExCo Member, IPS Webinars, Greece

Panelist:
- Jude Nwokike, Vice- President US Pharmacopeia, USA

Facilitar el acceso a los medicamentos: Bioequivalencia - Metodologías In Vitro para la Demostración de Equivalencia Terapéutica

Sesión II: Bioequivalencia - Sistema de Clasificación Biofarmacéutica: Fundamentos y aplicaciones a las bioexenciones

Este webinar tiene como objetivo presentar los conceptos:

• Definiciones e hipótesis
• Fundamentos del modelo
• Números adimensionales
• Clases y factores limitantes de la absorción

Moderadora:
-Talita Ferreira, FIP Coordinadora de Proyectos de bioexención en Latinoamérica, Brasil

Panelista:
-Pablo González, CEO Innovation and Biopharmaceutical Evaluation Center, Chile

This event is to update pharmacy professionals about managing workforce demand in a pandemic – now and in future. Case studies will be presented from countries across the globe. These will address how we ensure continuity of workforce supply during this and future pandemics, how can we reduce demand on the workforce and the role of healthcare regulators play.

Aim
To present to attendees approaches for managing workforce demand in a pandemic.

Learning objectives
1. Discuss how continuity of workforce supply can be managed during pandemics
2. Discuss how demand for the pharmaceutical workforce can be reduced during pandemics
3. Describe the impact of COVID-19 pandemic on the pharmacy workforce
4. Explain how pharmacists can be prepared for the role of vaccinator.

Moderator:
- Christopher John, FIP Lead for Data and Intelligence, FIP, UK

Panelists:
- Mariet Eksteen, Global Lead for FIP Development Goal 7: Advancing Integrated Services; Professional Development Officer, Pharmaceutical Society of South Africa (PSSA), South Africa
- Chima Amadi, Global Lead, FIP Development Goal 13 (Workforce Policy Formation); Education and Training Personnel Pharmacists’ Council Nigeria, Nigeria
- Rula Darwish, Exco committee FIP academic section WDG9 Lead; Professor School of Pharmacy/ The University of Jordan, CPD Chair in JPA,  Jordan
- Bärbel Holbein, FIP Global Lead for DG7 Advancing integrated services; Lecturer University of Bremen, Germany

The Pharmacy Education Journal (PEJ) continues to publish peer-reviewed manuscripts in the general scope of practise domain of pharmacy education (at all stages) and workforce development research and evaluation. PEJ is planning for widening scope by introducing educationally-related short, rapid response articles targeting non-traditional authors (non-academics) in Practice and Science sectors. PEJ is a key global dissemination route.

Event outcomes:

1 Showcase what did PEJ achieve during 20 years, how it was done and present the new plans.
2 Highlight the importance of publishing in the pharmaceutical workforce and education field.
3 Explain the steps from submission to publication: what happens behind the screen and who does it and provide some tips for authors.

Moderators:
- Marwan Akel, Projects Manager – Workforce development, evidence & impact Journal Editor – PEJ, FIP, Lebanon
- Sherly Meilianti, FIP Data and Intelligence Specialist, FIP, Indonesia

Panelists:
- Ian Bates, Director of the FIP Global Pharmaceutical Observatory, Chair of pharmacy education University College London, UK
- Lilian M. Azzopardi, Prof. of Pharmacy Department of Pharmacy, Faculty of Medicine and Surgery, University of Malta President, European Association of Faculties of Pharmacy, Malta
- Judilynn L. Niedo-Solidum, Prof. at University of the Philippines Manila College of Pharmacy, Philippines
- Rudi Hendra, Associate professor Indonesian Pharmacists Association, Indonesia
- Shane Desselle, RPh, PhD, FAPhA Professor of Social and Behavioral Pharmacy Touro University California College of Pharmacy, USA
- Jennifer Marriott, Adjunct Associate Professor, Australia

Substandard and falsified medicines, along with a lack of adherence to medication regimens, pose a threat to public health worldwide. It is possible to deliver pharmaceutical care services that address these challenges using digital healthcare techniques and approaches. Globally, digital health faces many challenges and concerns, despite its potential to impact pharmaceutical care.

FIP and the Global Pharmaceutical Observatory are launching a new needs assessment programme entitled "How can digital health support national pharmaceutical care delivery? A regional and global assessment of priorities and challenges", with an emphasis on medication adherence and fighting SF medicines.

This regional and global needs assessment programme will include a series of six regional events, culminating in a private global roundtable and a summary report.

In this regional event we will facilitate a regional discussion about ongoing digital health interventions or solutions that detect, report, and act against false or substandard medicines, and how to facilitate patient adherence, as well as the challenges leadership bodies and nations face in implementing digital health solutions in pharmaceutical care delivery in Africa.

Moderator:
-Prosper Hiag, President, African Pharmaceutical Forum, Cameroon

Facilitators:
-Anyango Esther, FIP - YPG Early Career Regional Supporter Africa Health Business (AHB), Kenya
-Farah Aqqad, FIP Regional Engagement, Support and Development Manager, Jordan

Panelists:
-KWABENA ASANTE OFFEI, Vice-President Pharmaceutical Society of Ghana (PSGH), Ghana
-Vigil Edward Prah-Ashun, Head of Intelligence Food and Drugs Authority, Ghana
-Redouane Soualmi, Secretary general Algerian Pharmaceutical Federation, Algeria
-Brent Sin Hidge, Hospital Pharmacist / Project Co-ordinator Netcare Blaauwberg Hospital, Cape Town, South Africa
-Mariet J Eksteen, Professional Development and Support Pharmaceutical Society of South Africa, South Africa

Constipation is a common symptom pharmacists encounter in daily practice. It is often a self-limiting symptom that can be adequately managed in the community through the use of non-prescription medicines, as well as dietary and lifestyle measures. This event will explore how community pharmacists may support the management of constipation and empower individuals for optimal self-care.

By the end of the session participants should be able to:
• Understand the role of pharmacists in managing constipation in the community
• Understand the influence of fibre, exercise, and fluids in constipation
• Explore the complications of constipation medicines, especially in older adults

Moderator:

- Marwan Akel, FIP Projects Manager - Workforce development, evidence & impact, Lebanon

Panellists:

- Safwan Jihan, Assistant Dean, Lebanese International University / School of Pharmacy, Lebanon 
- Madisch, Ahmed, Senior Consultant and Head, Center of Gastroenterology Bethanien, Germany 
- João Rafael Gonçalves, Community pharmacist, Portugal

Facilitar el acceso a los medicamentos: Bioequivalencia - Metodologías In Vitro para la Demostración de Equivalencia Terapéutica

Sesión I: Bioequivalencia

Sesión en Español

Este webinar tiene como objetivo presentar los conceptos:

• Medicamentos genéricos
• Definiciones
• Qué es bioequivalencia?
• Tipos de estudios
• Estudios farmacocinéticos:

o Diseños
o Consideraciones clínicas, analíticas y estadísticas

• Casos especiales

Moderadora:
- Talita Ferreira, FIP Coordinadora de Proyectos de bioexención en Latinoamérica, Brasil

Panelista:
- Pablo González, CEO, Innovation and Biopharmaceutical Evaluation Center, Chile

In order to ensure pharmacists maintain currency and quality in their practice, mandatory continuing professional development (CPD) programmes have been implemented by regulatory authorities as part of the licence renewal requirements for continuing practice. This webinar will provide information on the countries having a mandatory CPD programme, the various types of programmes, the regulations and the overall value and monitoring. In addition, information will be provided on CPD for specialized areas of practice, as part of returning to practice and some new concepts to insure currency and quality.

The attendees will learn:
-the overall importance of a mandated CPD programme from a quality assurance and patient safety perspective ;
-the variations of CPD programmes currently in place in various countries;
-the legislation/regulations in place mandating a CPD programme to maintain currency and enhance competence, quality assurance and patient safety;  
-recertification programs for "specialization" and "return to practice"; and,
-other innovative way to insure quality and currency of pharmacists.

Moderator:
- Brett Simmonds, Chair Pharmacy Board of Australia, Australia

Panelists:
- Carine Wolf-Thal, Chair of the National Council of the French Chamber of Pharmacists, France
- Michael Pead, Chief Executive Pharmacy Council of New Zealand, New Zealand
- Trish Farrelly, Manager Registration and Competence Assurance, Pharmacy Council of New Zealand, New Zealand
- Joe R. Anderson, Assistant Dean for Curricular Affairs and Associate Professor of Pharmacy Practice and Administrative Sciences, The University of New Mexico College of Pharmacy, USA

Gastrointestinal health and digestive wellness can be influenced by several lifestyle factors, including diet and stress, and using certain types of medicines. It is important for pharmacists to consider these factors when interacting with patients who present with such symptoms. Different non-prescription medicines are available to treat symptoms related to GI complaints and digestive wellness, rendering pharmacies key access points for trusted advice and access to self-care products which can provide relief and care to affected individuals. This event marks the World Digestive Wellness Day (29 May).

By the end of the session participants should be able to:
• Understand the role of pharmacists in providing advice on digestive wellness
• Understand the relationship between gut wellness and immunity
• Identify practical ways to support better digestive wellness in the community

This event discusses current evidence for the impact of the pharmaceutical workforce, pharmacy practice and pharmaceutical science.  It discusses and evidence-based approach and identifies challenges and opportunities for generating evidence that will advance the profession.

Aim
To showcase how data and intelligence can be used to provide evidence of impact of pharmaceutical practice, science and education/workforce.

Learning objectives

• Discuss approaches to securing evidence for the impact of the pharmaceutical workforce and pharmaceutical services.
• Discuss strategies and programmes in place to enable timely access to safe, effective and affordable medicines.
• Identify challenges and opportunities for generating evidence of impact.

Moderator:
- Christopher John, FIP Lead for Data and Intelligence, UK

Panellist: 

- Noe Garin Escriva, Hospital Pharmacist, Hospital de la Santa Creu i Sant Pau, Spain
- Harriet Rachel Kagoya, Uganda
- Safa Damiati, Assistant Professor, King Abdulaziz University, Suadi Arabia
- Sherly Meilianti, FIP Data and Intelligence Specialist, Indonesia
- Hilwan Yuda Teruna, Vice President, Indonesian Pharmacists Association, Indonesia

The FIP Hospital Pharmacy Section (HPS) has set out to develop its strategy for the next 5 years. In early 2022, the FIP HPS developed a survey to identify how the FIP HPS can assist FIP Vision/Mission and FIP Development Goals. This survey was sent to FIP Hospital Pharmacy Executive Committee members, Chairs of Committees/Observers, Past Executive Committee members, Hospital Pharmacy Member organisations and regional forums. Results of the survey will be presented with a discussion on the FIP HPS strategy.

Learning objectives:
- To know the results of the FIP HPS strategy survey
- To identify priorities areas for the FIP HPS over the next 5 years
- To participate in the future direction of the FIP HPS

Chair:
-Jonathan Penm, Secretary, FIP Hospital Pharmacy Section, Senior Lecturer The University of Sydney- Australia

Panelist:
-Robert Moss, President, FIP Hospital Pharmacy Section- the Netherlands

With the COVID-19 pandemic, effective use of educational technologies has become essential. Many different aspects of technology have been introduced or further expanded, including remote experiential learning or simulations for virtual patient care. At the same time, artificial intelligence enabled faculties to accelerate and advance research and clinical care in the pharmaceutical sciences and clinical pharmacy practice.

Introduction and implementation of any technology-enabled education and training includes many success factors such as technology literacy amongst educators and students. To enhance technology-enabled pharmaceutical education, this digital event will outline good practices and engage participants in identifying a SWOT (Strengths, Weaknesses, Opportunities, and Threats) of technology and AI use in education.

At the end of this session, participants will: 
1.Learn about current and future good practices about the educational technologies used in higher/pharmaceutical education
2.Contribute to the development of a SWOT in using Technology & AI in pharmaceutical education
3.Identify ways to enhance quality of education and academic capacity by utilizing technology and AI in pharmaceutical education

Co-chairs:
- Lilian Azzopardi, Dean Department of Pharmacy, University of Malta, Malta
- Jaime Acosta Gómez, FIP Community Pharmacy Section, FIP Technology Forum co-chair, FIP COVID19 Expert Advisory Group member; Community Pharmacist and pharmacy owner Farmacia Acosta, Spain

Panelists:
-Mia Sivén, Vice-Dean University of Helsinki, Finland
-Francesca Wirth, Senior Lecturer University of Malta, Malta
-Daniel Malone, Pharmacy Course Director Monash University, Australia

Facilitator:
-Aysu Selcuk, FIP AIM Advisory Committee Member, FIP Education and Primary Health Care Policies Specialist, Turkey

This event will discuss the role of community pharmacists in promoting oral health and the links between oral health and other non-communicable diseases. Also, the event will address the needs for additional training, interprofessional education and collaborative practice models between dentistry and pharmacy. Key interventions by community pharmacists in oral health care from different parts of the world will be presented.

Aim: To discuss the role of pharmacists in oral health, describe how pharmacists’ interventions in oral health can contribute to the prevention of non-communicable diseases, and explore interprofessional education and collaborative practice models between dentistry and pharmacy.

Learning objectives:
1. Understand the importance of oral health in the prevention of non-communicable diseases (NCD), such as cardiovascular and respiratory diseases, cancer and diabetes;
2. Explore the role of community pharmacists in promoting oral health care;
3. Discuss the need for oral health care training and education resources that support pharmacists deliver improved and responsive oral health care interventions;
4. Explore interprofessional collaborative practice models between dentists and pharmacists.

This webinar will announce a new partnership between FIP and Curriculo Solutions to introduce our members to the newly FIP Seal-awarded programme: “Pharmacists for the Future Programme” (PFP).

Curriculo is a UK based training company specialising in leadership and management skills development and career management. They work across various sectors including corporate, health care, education and sport.

The PFP focuses on the development of personal, social and professional skills and provides a strong foundation in the development of key leadership capabilities. The programme aligns with Development Goal 9: Continuing professional development strategies and addresses a skill gap that has been identified by members in leadership development.

During the event, FIP and Curriculo will:

• announce the new partnership for the FIP-sealed PFP.
• describe aspects of the provision and partnerships programme at FIP.
• describe the PFP and hear from previous participants in the programme through the sharing of testimonials.
• describe how FIP members can benefit from this programme.

This event is to update pharmacy professionals about the range of therapeutic options currently available for COVID-19. It will take an evidence-based approach and also look at future development of therapeutic agents.

Aim
To update attendees on the latest therapeutic advances against COVID-19

Learning objectives
1. Explain which medicines are available that target the virus or provide symptom control
2. Discuss which medicines will be effective against new variants.
3. Describe what other medicines are available and what is the evidence for them.
4. List medicines in the pipeline for treating COVID-19

Moderator:
-Christopher John, FIP Lead for Data and Intelligence, FIP - UK

Panelists:
-Syed Shahzad Hasan, Senior Research Fellow University of Huddersfield-UK
-Trevor Jones, Visiting Professor King’s College London - UK

Early feasibility clinical study was performed to assess the feasibility and tolerability of syringe pump-driven, constant rate (20µl/s), 1-20cP, 5 and 10ml subcutaneous placebo injections to the thigh (5ml only) and abdomen in 32 healthy adults. Endpoints include injection feasibility, depot location, pressure, subject pain tolerability/acceptability and the corresponding tissue effects.

Session Outline:

• Demonstrate the feasibility and broad acceptability of subcutaneous injections up to 10ml and 20cP administered without a permeation enhancer

• Determine if injection site tissue effects are visible and transient as well as the impact of injection site, volume and viscosity on these patterns

• Explore the relationship between subjects’ pain/acceptability and the injection site, volume and/or viscosity

Moderator

- Mathew Cherian, Consultant, Executive Committee Member (IPS), USA

Panellist 

- Wendy D Woodley, Staff Scientist II, Translational & Clinical Sciences, BD Technologies and Innovation, USA

Around the world, community pharmacies play an increasingly consolidated role in vaccination. During the pandemic, pharmacies’ accessibility made them a convenient place for vaccination against COVID-19 in several countries, increasing vaccination coverage and helping achieve herd immunity. As the world slowly begins to emerge from the pandemic, this event will discuss the role of community pharmacies in COVID-19 booster vaccination, and their challenges in vaccine supply logistics and cold storage solutions, particularly in a post-pandemic scenario. Key interventions by community pharmacists in vaccine supply logistics linked to COVID-19 from different parts of the world will be presented.

Learning objectives:

1. Understand the supply chain and distribution process of COVID-19 vaccines from manufacturer to hospitals, community pharmacies, and the public;

2. Explore the role of community pharmacies in vaccine supply logistics for COVID-19;

3. Discuss the challenges of COVID-19 booster vaccination supply logistics and cold storage solutions in community pharmacies, particularly in a post-pandemic scenario;

4. Explore supply models that involve community pharmacies contributing to population vaccination coverage in a post-pandemic scenario.

Moderator:
- Catherine Duggan, Chief Executive Officer FIP, the Netherlands

Panellists:
- Vibhu Paudyal, Associate Professor in Clinical Pharmacy University of Birmingham, UK
- Ronald T. Piervincenzi, Ph.D., Chief Executive Officer USP, USA
- Loganathan Fahrni, Senior lecturer and pharmacist Universiti Teknologi MARA, Malaysia

The importance of vaccines creates opportunities for pharmacists and pharmacies to contribute to improving vaccination coverage. Since the publication of FIP’s 2020 report on vaccinations highlighting the role of pharmacists and pharmacies in this area, there has been a significant expansion in pharmacy-based vaccination and the scope of vaccines delivered by pharmacists and the pharmacy workforce. To kick off World Immunisation Week, this digital event will provide an overview of that expansion for tetanus, diphtheria, acellular pertussis booster, COVID-19, and meningitis vaccines. Moreover, it will allow participants to hear from countries in various stages of advocating for a broader role for pharmacists in vaccination.

Learning objectives:

1. To identify the current role of the pharmacist in tetanus, diphtheria, acellular pertussis booster, COVID vaccination, and meningococcal meningitis vaccination.
2. To explore needs, drivers, and barriers for expanding that role in countries that have regulated pharmacy-based vaccination services.
3. To give examples from countries with pharmacy-based vaccination services  in advocating a broader role for pharmacists in vaccination

Moderators:

- Ian Bates, Director of the FIP Global Pharmaceutical Observatory, Chair of pharmacy education, University College London, United Kingdom

- Manjiri Gharat, FIP Vice-President, India 

Panellists:

- Carine Wolf-Thal, Chair of the National Council of the French Chamber of Pharmacists, French Chamber of Pharmacists, France

- Zhi Shan Sujata, Pharmacist, Malaysian Pharmacists Society, Malaysia

-  Sham Moodley, Pharmacist,  Pharmaceutical Society of South Africa/Independent Community Pharmacy Assoc, South Africa

- Zeid Kilani, President, Jordan Pharmacists Association, Jordan

- Mas Rahman Roestan, Operational Director of PT Biofarma and Expert Council of Indonesian Pharmacists Association, Indonesian Pharmacists Association, Indonesia

- Irma Beatriz Caponi, Farmacéutica, COFA, Argentina

Facilitators & Speakers:

- Christopher John, FIP Lead for Data and Intelligence, UK 

- Zheng Kang Lum, PhD candidate, National University of Singapore, Singapore

- Allie Jo Shipman, Director, State Policy, National Alliance of State Pharmacy Associations, USA

- Sherly Meilianti, FIP Data and Intelligence Specialist, Indonesia

This webinar is the first of the Precision Medicine Webinar Series, which will discuss the current state and future of precision medicine in research and practice, including the ongoing technological advances and challenges and opportunities for the pharmacy profession to address. This webinar will introduce:

- The needs, goals and principles of precision medicine

- Examples of current implementation across disease categories

- Safety aspects and challenges

- Limitations of current approaches and needs for development

At the end of this session, participants will: 

1. Understand the goals of precision medicine
2. Be familiar with some examples of its implementation
3. Be aware of current limitations and remaining challenges

Co-Chairs:

- Donnacha Fitzgerald, FIP Technology Forum member, Predoctoral Fellow, The European Molecular Biology Laboratory (EMBL) and Heidelberg University Hospital, Germany
- Stephanie Huang, Associate Professor, Department of Experimental and Clinical Pharmacology, University of Minnesota, USA

Panellists:

- Ejner Moltzen, Chair, International Consortium for Personalized Medicine, Denmark
- Mark Dunnenberger, Director, Pharmacogenomics Center for Personalized Medicine NorthShore University HealthSystem, USA

Over the past 2 decades, virtual education evolved as a new pedagogy within education. Following the experience from the unexpected drastic shift to remote learning and virtual education as a result of the COVID-19 pandemic, educators are faced with dilemmas of how to strike a balance between face-to-face modalities and the virtual platform. Remote learning and virtual education provide opportunities and leadership to develop hybrid models of teaching is now being considered. The webinar will seek to expose experiences and share examples of such opportunities and how to lead faculty towards incorporating the virtual education while ensuring quality education.

The participants who join the webinar will;
• Address assessment of quality of virtual education at the schools of pharmacy
• Reflect on the extent of remote learning after COVID-19 in pharmacy education
• Discuss approaches towards the development of hybrid education in pharmacy schools

Chairs:
-Pierre Moreau, FIP AIM Chair, Dean Kuwait University, Kuwait
-Lilian Azzopardi, FIP AIM Advisory Committee Member, Dean Department of Pharmacy, University of Malta, Malta
-Hanan Refaat, FIP AIM Advisory Committee member, Dean Future University in Egypt, Egypt

Panelists:
-Seif El Hadidi, FIP AIM member, Lecturer in Clinical Pharmacy, Future University in Egypt, Egypt
-Brian Hemstreet, FIP AIM working group member, Associate Dean for Student Affairs and Professor University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, USA
- Jennifer Pham, Clinical Associate Professor, Clinical Pharmacist – Neonatal / Pediatrics, University of Illinois at Chicago College of Pharmacy, USA
- Alan Lau, Professor and Director, International Clinical Pharmacy Education University of Illinois at Chicago College of Pharmacy, USA

Facilitator:
-Ozge Ozer, Educational Partnership Manager, Turkey

This is the COVID-19 programme initiator and will set the scene: why this programme; main outcomes; FIP advocacy role. It aligns with 800 days since pandemic and will launch SustainabilityRx website/ Visualisation (FIP’s response to COVID-19) with a focus on pandemic preparedness.


Learning objectives
1. Describe the functionality of the SustainabilityRx website
2. Outline the current COVID-19 situation from the perspectives of practice, science and workforce/education;
3. Consider steps that can be taken to prepare for future pandemics.

Moderators:
- Christopher John, FIP Lead for Data and Intelligence, FIP, UK
- Dr Lina Bader/Dr Sherly Meilianti FIP Lead for Workforce Transformation/FIP Data and Intelligence Specialist, FIP-Saudi Arabia

Panelists:
- Dr Hoai-An Truong, Professor and Director of Public Health, School of Pharmacy & Health Professions, University of Maryland Eastern Shore, USA
- Dr John Grabenstein, Member of FIP COVID-19 Expert Advisory Group, President Vaccine Dynamics SP, USA
- Prof. Trevor Jones, Visiting Professor King’s College London, UK
- Dr Ally Dering-Anderson, Current member of the FIP COVID-19 Expert Advisory Groupm, Clinical Associate Professor in the Department of Pharmacy Practice & Science University of Nebraska College of Pharmacy, USA
- Shaun Gleason, FIP Hub DG1 Lead, Member of the COVID-19 Expert Advisory Group, Assistant Dean for Distance Degrees and Programs; Associate Professor, Skaggs School of Pharmacy and Pharmaceutical Sciences University of Colorado Anschutz Medical Campus, USA

Epilepsy is a disorder that afflicts approximately 50 million people worldwide and the WHO has declared epilepsy as a public health imperative. Medications are the mainstay of treating epilepsy, so pharmacist have great role to play in improving the care of people with epilepsy. This Webinar will explore the findings of the recent WHO report on epilepsy, describe ways that pharmacists can be involved in caring for patients with epilepsy, consider advances in new medications, and discuss the challenges of access to medications for many people worldwide.

Learning Objectives:
1. Identify the main barriers to appropriate care of patients with epilepsy as described in the 2019 WHO report on epilepsy.
2. Describe ways that pharmacists can improve the care of patients with epilepsy.
3. Incorporate new antiseizure medications into treatment regimens for epilepsy.
4. Take steps to improve patient access to good quality seizure medications.

Moderator:
-Filipa Alves da Costa, ExCo member of the FIP Social and Administrative Pharmacy Section, Portugal

Panelists:
-Timothy Welty PharmD, College of Pharmacy and Health Sciences Drake University Des Moines, Iowa, USA
-McKenzie Grinalds, PharmD School of Pharmacy Cedarville University Cedarville, Ohio, USA
-Thanarat Suansanae PharmD, School of Pharmacy, Mahidol University Bangkok, Thailand
-Melody Ryan, Professor, University of Kentucky, USA

Approximately 90 percent of prescriptions in the US are generics that often are the product of an intricate global supply chain. The Office of Generic Drugs (OGD) is involved in efforts to advance the international harmonization of scientific, technical and regulatory standards for generic drug development. OGD continues global efforts with a focus on prioritizing future topics for generic harmonization that will include more complex generic drugs. The envisioned outcome of these global efforts is reduced time and cost of product development, consequently improving patient access to more affordable medicines. OGD Global Affairs identifies opportunities and challenges as those national regulations are being developed and implemented positioning regulators proactively on the path of convergence.

Learning Objectives:
1) FDA’s views on global harmonization of regulatory process for generic drugs
2) Identifying opportunities and challenges in arriving at harmonized processes globally.

Moderators:
-Dr Mathew Cherian, Executive Committee Member, Industrial Pharmacy Section, Consultant, USA
-Mr Desai Kaushik , Associate ExCo Member, Industrial Pharmacy Section (FIP), Secretary General, International Pharmaceutical Excipient Council of India, India

Panelist:
-Sarah Ibrahim, Director CDER, FDA, USA

In many countries, vaccination coverage rates are suboptimal, and vaccination services are largely focused on childhood. Goals to expand vaccination pathways include to have more and more easily accessible vaccination points, and more professionals who can deliver the service to more people and offer evidence-based advice on vaccines. This event will discuss the drivers and barriers to interprofessional understanding, cooperation and task sharing in the area of vaccination in each region, and the regulatory authority granted to different healthcare professionals to prescribe and/or administer vaccines.

Learning objectives:
- Identify drivers and barriers related to the regulatory landscape of vaccination in the region
- Learn about examples of best practices in terms of interprofessional cooperation and task-sharing involving pharmacists in the area of vaccination
- Explore the plans for switching from a pandemic to an endemic response in the region, including the role of pharmacist in vaccination, and in patient care and treatment

Moderators:
- Dr Samira Shammas, FIP Vice president, Jordan
- Jorge Batista, Portuguese Pharmaceutical Society, Portugal

Panelists:
- Dr Nadia Al Mazrouei, President, EMRO Pharm Forum, UAE
- Dr Pascale Salameh, President, Lebanese Order of Pharmacists, Lebanon
- Dr Maha al Jaghbeer, Director of Laboratories directorate, Jordan Food and Drug Administration, Jordan
- Dr Dixon Thomas, Associate Professor - Department of Pharmacy Practice, College of Pharmacy, Gulf Medical University, UAE

In many countries, vaccination coverage rates are suboptimal, and vaccination services are largely focused on childhood. Goals to expand vaccination pathways include to have more and more easily accessible vaccination points, more professionals who can deliver the service to more people and offer evidence-based advice on vaccines. This event will discuss the drivers and barriers to interprofessional understanding, cooperation and task sharing in the area of vaccination in the region, and the regulatory authority granted to different healthcare professionals to prescribe and/or administer vaccines. 

Learning objectives:

- Identify drivers and barriers related to the regulatory landscape of vaccination in the region

- Learn about examples of best practices in terms of interprofessional cooperation and task-sharing involving pharmacists in the area of vaccination

- Explore the plans for switching from a pandemic to an endemic response in the region, including the role of pharmacist in vaccination, and in patient care and treatment.

Moderators:

- Manjiri Gharat, FIP Vice President, India
- Al Carter, Executive Director, National Association of Boards of Pharmacy, USA

Panellists:

- Tisara De Silva, President, Pharmaceutical Society of Sri Lanka, Sri Lanka
- Rao V. S. V. Vadlamudi, Professional Secretary, SEARPharm Forum, India
- Nurul Pariang, President, Indonesian Pharmacists Association, Indonesia
- Pramod Yeole, Acting President, Pharmacy Council of India, India

Ongoing learning and professional development are key to components of every occupation. This is especially true for pharmacy technicians working in a constantly-evolving practice landscape. This session will address professional development and advanced training for pharmacy technicians across the world.

Learning Objectives:
● Recognize strategies for continuous learning and professional development
● Identify professional development opportunities designed for pharmacy technicians
● Describe advanced training progams for pharmacy technicians

Moderators: 

- Ryan Burke, Director of Professional Affairs, Pharmacy Technician Certification Board, United States

Panelists:

- Nichole Foster, Program Director, Pharmacy Technician Training Program, Vanderbilt Medical Center, United States

- Peter Karegwa Mwangi, National Chairman, Kenya National Union of Pharmaceutical Technologists, Kenya

- Katherine Watkinson, Branch Liaison Executive, Association of Pharmacy Technicians, UK

Español

Para abogar por una implementación más amplia y armonizada del Sistema de Clasificación de Biofarmacéuticos (BCS) en los países de América Latina, la FIP está apoyando a los líderes regionales en la concientización sobre esta vía regulatoria basada en la ciencia diseñada para acelerar la aprobación del mercado de medicamentos genéricos seguros y efectivos. La tercera parte de esta serie de seminarios web diseñada específicamente para la región de América Latina desde la perspectiva de las agencias reguladoras sobre cómo se está implementando la legislación de bioequivalencia. Los expertos abordarán la base legislativa de las regulaciones de bioequivalencia y discutirán las oportunidades de armonización dentro de la región.

Sesión en Español con slides en inglés

Este webinar tiene como objetivo:

• • Presentar la legislación de Bioequivalencia de México, Colombia y Perú.
• • Alinear cómo las empresas deben establecer los requisitos del BSC.
• • Compartir el conocimiento regulatorio del BSC en la región.

Moderadora:

Talita Ferreira, Coordinadora de Proyectos de bioequivalencia en Latinoamérica, FIP, Brazil

Panelistas:
-Zulema Rodríguez Martinez, Coordinador del área de Bioequivalencia, Comisión Federal para la Protección contra Riesgos Sanitarios (Cofepris), México
-Diego Alejandro Gutierrez Triana, Director de medicamentos y productos biológicos, Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA), Colombia
-David Salirrosas Llanos, Especialista en evaluación sanitaria de medicamentos, Dirección General de Medicamentos (DIGEMID), Perú

Portugués

Para defender uma implementação mais ampla e harmonizada do sistema de classificação de produtos biofarmacêuticos (BCS) em países latino-americanos, a FIP está apoiando os líderes regionais na conscientização para esta via regulatória com base científica projetada para acelerar a aprovação do mercado de medicamentos genéricos seguros e eficazes. A terceira parte desta série de webinars projetada especificamente para a região da América Latina sob a perspectiva das agências regulatórias como está sendo implementada as legislações de bioequivalências. Os especialistas irão abordar a base legislativa dos regulamentos de bioequivalência e discutir as oportunidades de harmonização dentro da região.

Sessão em Espanhol com slides em Inglês

Este webinar tem como objetivos:

• Apresentar as legislações de Bioequivalência do México, Colômbia e Peru.
• Alinhar como as empresas devem estabelecer os requisitos de BSC.
• Compartilhar o conhecimento regulatório de BSC na região.

Moderadora:

Talita Ferreira, Coordenadora do Projeto Bioequivalência da América Latina, FIP, Brasil

Panelistas:
-Zulema Rodríguez Martinez, Coordenadora da área de Bioequivalência, Comissão Federal de Proteção contra Riscos Sanitários (Cofepris), México 
-Diego Alejandro Gutierrez Triana, Diretor de medicamentos e produtos biológicos, Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA), Colômbia
-David Salirrosas Llanos, Especialista em avaliação sanitária de Medicamentos, Direção Geral de Medicamentos (DIGIMED), Perú

In many countries, vaccination coverage rates are suboptimal, and vaccination services are largely focused on childhood. Goals to expand vaccination pathways include to have more and more easily accessible vaccination points, more professionals who can deliver the service to more people and offer evidence-based advice on vaccines. This event will discuss the drivers and barriers to interprofessional understanding, cooperation and task sharing in the area of vaccination in the region, and the regulatory authority granted to different healthcare professionals to prescribe and/or administer vaccines.

Learning objectives:

- Identify drivers and barriers related to the regulatory landscape of vaccination in the region
- Learn about examples of best practices in terms of interprofessional cooperation and task-sharing involving pharmacists in the area of vaccination
- Explore the plans for switching from a pandemic to an endemic response in the region, including the role of pharmacist in vaccination, and in patient care and treatment.

Co-moderators:

- Jocelyn Chaibva, Vice president, African Pharmaceutical Forum, Zimbabwe
- Ronald Guse, Chair FIP Regulators Forum, Canada

Panellists:

- Samuel Adekola, Immediate past national chairman & the executive secretary/ program director of the ACPN foundation. Nigeria
- Djamila Reis, CEO, Association of Pharmacists from Portuguese-Speaking Countries, Cape Verde
- Portifa Mwendera, President, Pharmaceutical Society of Zimbabwe, Zimbabwe
- Lucas Nyabero, Interim CEO, Pharmaceutical Society of Kenya, Kenya
- Franck Nana, President, National Council of Pharmacists, Cameroon
- Amath Niang, President, Ordre des Pharmaciens du Sénégal, Sénégal
- Imoiboho Williams, Project Manager, Adverse Events Following Immunization Surveillance Institute of Human Virology, Nigeria
- Redouane Soualmi, Chairperson of External Relations, Algerian Pharmacy Federation, Algeria
- Ezinne Onwuekwe, Vaccine Programme Coordinator, Africa CDC, Ethiopia

Dans de nombreux pays, les taux de couverture vaccinale sont sous-optimaux et les services de vaccination sont essentiellement axés sur l'enfance.

Les objectifs visant à développer les parcours de vaccination consistent notamment à disposer de points de vaccination plus nombreux et facilement accessibles, d'un plus grand nombre de professionnels capables de fournir le service à un plus grand nombre de personnes et d'offrir des conseils sur les vaccins fondés sur des données probantes.

Cet événement permettra de discuter des moteurs et des obstacles à la compréhension interprofessionnelle, à la coopération et au partage des tâches dans le domaine de la vaccination dans la région, ainsi que de l'autorité réglementaire accordée aux différents professionnels de la santé pour prescrire et/ou administrer les vaccins.  

Objectifs d'apprentissage :

•       Identifier les moteurs et les obstacles liés au paysage réglementaire de la vaccination dans la région. 

•       Découvrez des exemples de bonnes pratiques en matière de coopération interprofessionnelle et de partage des tâches impliquant des pharmaciens dans le domaine de la vaccination. 

•       Explorer les plans pour passer d'une réponse pandémique à une réponse endémique dans la région, y compris le rôle du pharmacien dans la vaccination, et dans les soins et le traitement des patients. 

In many countries, vaccination coverage rates are suboptimal, and vaccination services are largely focused on childhood. Goals to expand vaccination pathways include to have more and more easily accessible vaccination points, and more professionals who can deliver the service to more people and offer evidence-based advice on vaccines. This event will discuss the drivers and barriers to interprofessional understanding, cooperation and task sharing in the area of vaccination in each region, and the regulatory authority granted to different healthcare professionals to prescribe and/or administer vaccines.

Learning objectives:
- Identify drivers and barriers related to the regulatory landscape of vaccination in the region
- Learn about examples of best practices in terms of interprofessional cooperation and task-sharing involving pharmacists in the area of vaccination
- Explore the plans for switching from a pandemic to an endemic response in the region, including the role of pharmacist in vaccination, and in patient care and treatment

Moderators:

- Lars-Åke Söderlund, FIP Vice President, Sweden
- Ronald Guse, Chair of FIP Regulators Forum, Canada

Panelists:
- Michał Byliniak, Vice president, Polish Pharmaceutical Chamber, Poland
- Alain Delgutte, National Board Member, French Chamber of Pharmacists
- Inga Lilý Gunnarsdóttir, President, Pharmaceutical Society of Iceland, Iceland
- Jean-Pierre Michel, Member, European Union of Geriatric Medicine Society. European Interprofessional Council on Ageing, Switzerland
- Ema Paulino, President, National Association of Pharmacies, and member of the National Vaccine Advisory Committee, Portugal
- Roberto Tobia, President, Pharmaceutical Group of the European Union, Italy
- Mariano Votta, President, Active Citizenship Network, Italy

In many countries, vaccination coverage rates are suboptimal, and vaccination services are largely focused on childhood. Goals to expand vaccination pathways include to have more and more easily accessible vaccination points, and more professionals who can deliver the service to more people and offer evidence-based advice on vaccines. This event will discuss the drivers and barriers to interprofessional understanding, cooperation and task sharing in the area of vaccination in each region, and the regulatory authority granted to different healthcare professionals to prescribe and/or administer vaccines.

Learning objectives:
- Identify drivers and barriers related to the regulatory landscape of vaccination in the region
- Learn about examples of best practices in terms of interprofessional cooperation and task-sharing involving pharmacists in the area of vaccination
- Explore the plans for switching from a pandemic to an endemic response in the region, including the role of pharmacist in vaccination, and in patient care and treatment

Moderators:
- Magaly Rodríguez de Bittner, Vice president, Pharmaceutical Forum of the Americas, USA
- Anastasia Shiamptanis, Registrar, New Brunswick College of Pharmacists, Canada

Speakers:
- Bertrand Bolduc, President, Order of Pharmacists of Quebec, Canada
- Josélia da Silva Frade, Advisor on Professional Affairs to the president, Federal Council of Pharmacy, Brazil
- Eduardo Savio, President, Pharmaceutical Forum of the Americas, Uruguay
- Sofía Segura, Professor, University of Costa Rica, Costa Rica
- L. J. Tan, Chief Policy and Partnerships Officer, Immunize.org, USA
- Abraham S. Weekes, Council Member, Caribbean Association of Pharmacists, St. Lucia

En muchos países, las tasas de cobertura de vacunación no son óptimas, y los servicios de vacunación se centran principalmente en la infancia. Los objetivos para ampliar las vías de acceso a la vacunación incluyen disponer de más puntos de vacunación de fácil acceso, más profesionales que puedan prestar el servicio a un mayor número de personas y ofrecer asesoramiento basado en la evidencia sobre las vacunas. En este evento se debatirán los factores que impulsan y obstaculizan el entendimiento interprofesional, la cooperación y el reparto de tareas en el ámbito de la vacunación en la región, así como la autoridad normativa concedida a los distintos profesionales sanitarios para prescribir y/o administrar vacunas. 

Objetivos de aprendizaje:

- Identificar los impulsores y las barreras relacionadas con el panorama normativo de la vacunación en la región

- Conocer ejemplos de buenas prácticas en materia de cooperación interprofesional y de reparto de tareas con la participación de los farmacéuticos en el ámbito de la vacunación

- Explorar los planes para pasar de una respuesta pandémica a una endémica en la región, incluyendo el papel del farmacéutico en la vacunación, y en el cuidado y tratamiento de los pacientes.

In many countries, vaccination coverage rates are suboptimal, and vaccination services are largely focused on childhood. Goals to expand vaccination pathways include to have more and more easily accessible vaccination points, and more professionals who can deliver the service to more people and offer evidence-based advice on vaccines. This event will discuss the drivers and barriers to interprofessional understanding, cooperation and task sharing in the area of vaccination in each region, and the regulatory authority granted to different healthcare professionals to prescribe and/or administer vaccines.

Learning objectives:
- Identify drivers and barriers related to the regulatory landscape of vaccination in the region
- Learn about examples of best practices in terms of interprofessional cooperation and task-sharing involving pharmacists in the area of vaccination
- Explore the plans for switching from a pandemic to an endemic response in the region, including the role of pharmacist in vaccination, and in patient care and treatment

Moderators:
- Parisa Aslani, FIP Vice President, FIP, Australia
- Ron Guse, Chair FIP Regulators Forum, FIP, Canada

Panelists:
- Amrahi Buang, President, Malaysian Pharmacists Society, Malaysia
- John Jackson, President, Western Pacific Pharmaceutical Forum, Australia
- Michael Moore AM PhD, Chair of the WFPHA Global Taskforce on Immunization Adjunct Professor University of Canberra, Australia
- Tony Nelson, Chair of the Steering Committee, Immunisation Partnership Asia Pacific, Hong Kong
- Andi Shirtcliffe, Clinical Chief Advisor Pharmacy, Allied Health and National Immunisation Program. Office of the Chief Clinical Officers, Ministry of Health, New Zealand
- Stephanie Tay, Senior Manager, Chief Pharmacist’s Office, Ministry of Health, Singapore

Self-care is an integral part of healthcare systems, contributing to healthcare cost savings, better allocation of resources and improved health outcomes in the population. Pharmacists are well placed in the community to support health-related decisions and facilitate informed self-care. FIP aims to support pharmacists in this role through advocacy and by developing professional resources in the area of self-care. This event will showcase a variety of FIP publications, including the launch of a new handbook.

Learning Objectives:
Understand the contribution of self-care to universal health coverage (UHC)
Explore the role of pharmacists in supporting informed self-care
Showcase FIP’s materials in the area of self-care

Moderator:
-Sarah Dineen-Griffin, FIP CPS ExCo member - Australia

Panelists:
-Lars-Åke Söderlund, Vice-President, FIP Sweden
-Daragh Connolly, President Community Pharmacy Section, FIP Ireland
-Christopher John, FIP Lead for Data and Intelligence, FIP UK
-Rúben Viegas, FIP Practice Development Projects Coordinator, FIP Spain

The CPS Champion for Change 2021, Dr Odhiambo David, will share his vision on how pharmacists can better serve patients with mental health issues:
- Describe what service pharmacies should offer patients and/or healthcare systems to help tackle the mental health burden;
- In what ways can pharmacists support self-care and mental health patients having a more autonomous life; and
- How can digital health tools (either low or high tech) help community pharmacists improve outcomes and better support patients with mental health problems

Malaria is responsible for approximately 400 thousand deaths annually, resulting in an enormous public health burden on many of the tropical and subtropical countries. Although projects are ongoing in WHO, pharmaceutical companies and foundations, basic university-based research is also essential against for treatment and drug resistance in malaria. Engagement of young pharmaceutical scientists in the field is necessary to overcome this situation.

In this event, young PI and early carrier scientists / PhD students related to this scientific subject will be invited as speaker. Dr Eizo Takashima, Ehime University, Japan was invited as a speaker for preliminary lecture, and provide opportunity for young scientists to discuss about the science of malaria.

Learning objectives:

• Describe the development of malaria vaccine candidates.
• Defineseroepidemiology of malaria
• Recognize how early carrier pharmaceutical scientists can be involved in research on drug and vaccine development of malaria.

Moderators:
- Takuya Kumamoto, SIG NM Chair, Prof Hiroshima University, Japan
- Rebecka Isaksson, NGPS SIG Chair, Postdoctoral Research Associate UCL Department of Chemistry, UK

Panelists:
- Dr Eizo Takashima,Associate Professor, Ehime University, Japan
- Dr Wei-Chiao Huang, Post-doc State University of New York at Buffalo, US
- Dr Takaya Sakura, Assistant Professor Department of Molecular Infection Dynamics, Institute of Tropical Medicine (NEKKEN), Nagasaki University, Japan
- Khalid Garba Mohammed, Lecturer, Bayero University, Kano, Nigeria

At this event on World Cancer Day, we will explore innovations in pharmacy practice in the community and hospital pharmacy settings, in terms of supporting cancer patients throughout their journey. A panel of experts will present and discuss examples of innovative professional services in cancer prevention and screening, access to cancer treatments, adherence and continuity across transitions of care, among others.

The goal is to raise awareness of the important role that pharmacists can play in all areas of practice in terms of cancer prevention and management, in collaboration with other healthcare professionals.

Learning Objectives

• Identify and discuss the roles that community and hospital pharmacists can play in cancer prevention and management.
• Present examples of best practices of cancer-related professional services by pharmacists from around the world.
• Discuss the importance of supporting patients in a multi- and inter-professional approach
• Explore issues on the transitions of care, adherence to treatments and prevention and screening in cancer care

Moderators:
• Josep M. Guiu Segura, Director of Pharmacy and Medicines, Consortium of Health and Social Care of Catalonia, Spain
• Daragh Connolly, President, FIP Community Pharmacy Section, Ireland

Panelists:
• Marko Skelin M.Pharm PhD. Board member of the European Society of Oncology Pharmacy; Assistant Professor, Faculty of Medicine, University of Rijeka, Croatia
• Robert Duncombe, Chief Pharmacist, Director of Pharmacy, The Christie NHS Foundation Trust, Manchester, UK
• Jan de Belie, Professional Affairs Advisor, Pharmaceutical Group of the European Union, Belgium
• Kofi Boamah Mensah, Oncology Pharmacist at Komfo Anokye Teaching Hospital (KATH) and adjunct lecturer at the Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Science, Kwame Nkrumah University of Science and Technology (KNUST), Ghana

Establishing a correlation between in vitro tests and in vivo product performance has always been a challenge for the pharmaceutical industry.  Without a link between specifications and in vivo performance, drug product manufacturing processes are often performed under unnecessarily tight controls. Furthermore, implementing changes post-product market approval can be challenging in a complex global environment.  This webinar will describe traditional and novel approaches towards establishing in vitro in vivo correlations. The main focus will be on solid oral dosage forms, however other dosage forms will also be discussed.

Moderators:
-Andreas Abend, Senior Principal Scientist, MSD, USA
-Horst-Dieter Friedel, FIP Chair Special Interest Group Regulatory Sciences and Quality, Germany

Panelist:
-Patrick Marroum, Senior Director in Clinical Pharmacology and Pharmacometrics AbbVie, USA

Recent technological advancements have revolutionized clinical practice, and there is need for a pharmaceutical workforce that is well-equipped to embrace, innovate, and capitalize on the benefits of digital health. Findings from the 2021 FIP report on digital health in pharmacy education revealed the need to develop courses, training material and experiential learning opportunities to prepare a digitally literate pharmacy workforce.

The Academic Pharmacy Section, supported by the FIP Provision and Partnerships programme, and many FIP constituencies led a ONEFIP project to develop the first FIP-developed online Train the Trainer (TtT) course. At this event, we will reflect on the progress made to date, launch the TtT course, which targets academics as well as educators in any sector in pharmacy, and how this initiative builds on FIP competency frameworks and reports.

Event outcomes:
1. To describe FIP’s response following the release of digital health in pharmacy education report in 2021.
2. To provide an overview of the FIP Global Platform for Provision and Partnerships.
3. To launch the FIP Train the Trainer online course on FIPx and generate interest in the course

Moderators:
- Barry Bleidt, Prof. Nova Southeastern University College of Pharmacy, USA
- Naoko Arakawa, Assistant Professor in International Pharmacy University of Nottingham, UK

Panelists:
- Dr. Catherine Duggan, CEO FIP, the Netherlands
- Aukje Mantel-Teeuwisse, Director Utrecht University School of Pharmacy, the Netherlands
- Dr. Dalia Bajis FIP Lead for Provision and Partnerships FIP, Australia/Bahrain
- Nilhan Uzman, Lead for Education Policy and Implementation FIP, The Netherlands
- Jaime Acosta-Gómez, CPS Professional Secretary, Community pharmacist, Farmacia Acosta, Spain
- Prof. Lilian Azzopardi Head, AIM Advisory Committee member, Department of Pharmacy University of Malta, Malta
- Chu-Chen Cheng, Provision and Partnerships Remote Volunteer, Pharmacist FIP, Chaina Taiwan
- Genuine A. Desireh, Provision and Partnerships Remote Volunteer, Pharmacist FIP, Kenya

Medication errors and adverse events cause significant harm to patients’ health and well-being. At this event we will present an overview of the range of Medication Review (MR) services and their definition, highlighting the difference between them and particularly with Medicines Use Review (MUR) in light of recent international updates.

Learning Objectives
• Explore medication review services
• Define MR and MUR
• Present the FIP Toolkit on MR & MUR

Moderator:
Tim Chen, President of FIP Social and Administrative Pharmacy Section, President FIP Social and Administrative Pharmacy Section - Australia

Panelists:
-Filipa Alves da Costa, Assistant professor University of Lisbon, Portugal
-Kurt E. Hersberger, University of Basel, Switzerland
-Matthew Hung, Clinical Staff Pharmacist St. Mary’s Hospital, Montreal West Island Integrated University Health and Social Services Centre, Practice Development Projects Assistant (consultancy), Canada

The United Nations General Assembly proclaimed 24 January as International Day of Education, in celebration of the role of education for peace and development. And FIP AIM will be celebrating this special day with a webinar on mental health and wellbeing for academics.

Because the COVID-19 pandemic had led to considerable impact on our physical and mental wellbeing, mental health has become the ‘shadow pandemic’. At this webinar, cultivating mental health and resilience for academics will be highlighted and academic strategies for will be discussed to emphasize the benefits of improved mental health and wellbeing in achieving a better work-life integration.

The participants who join the webinar will;
1. Discover the importance of fostering academic resilience for mental health and wellbeing during unprecedented times and beyond,
2. Address the necessary reasons to raise mental health awareness among academics for students and workplace,
3. Identify institutional strategies in supporting mental health and wellbeing of academic staff and students,
4. Optimize mental health for academic performance in higher education.

Chairs:
-Pierre Moreau, Dean FIP, Kuwait University, Kuwait
-Toyin Tofade, Dean Howard University College of Pharmacy, USA
-Mohamad Rahal, Dean Lebanese International University, Lebanon

Panelists;
-Neil MacKinnon, Provost and Executive Vice President for Academic Affairs Augusta University, USA
-Betty Exintaris, Senior Lecturer, Monash University, Australia
-Fatos Ilkay Alp Yıldırım, Associate professor Istanbul University, School of Pharmacy, Turkey

Facilitators:
-Nilhan Uzman, FIP Lead for education policy and implementation FIP, The Netherlands
-Ozge Ozer, FIP Educational Partnership Coordinator, Turkey

Pharmacy teams are increasingly providing services that support people to self-care with their sexual health. This webinar will focus particularly on advice, screening and testing, as well as appropriate management of choices of medicines and products to support sexual health. A case study will be presented and the event will conclude with a panel discussion.

Aim:
To identify how the community pharmacy team can provide support to people to self-care with their sexual health.

Learning objectives:
1. Increase awareness of sexual health issues, how common they are, what impacts they have and how they can be managed;
2. Learn how to support people with their sexual health;
3. Discuss appropriate management in the choice of medicines and products for the self-care of sexual health.
4. Describe the role that pharmacist and their team can play in screening, testing, advising and educating people sexual health and how they can self-care.

Moderator:
- Leonila Ocampo, Member of the FIP Community Pharmacy Section; President, Asia Pacific Institute for Medication Management, Philippines

Panelists:
- Irene Serrano, Community Pharmacist, Spain
- Wael Ali, Egyptian Organisation of Pharmacy, Egypt
- Luna El Bizri, Founder and Manager, Lunapharm Pharmacy, Lebanon

The year 2020 saw the COVID-19 outbreak become a global pandemic which, even by 700 days at the end of 2021, has highlighted how much the world has had to change and we have had to adapt our lives, ways of working, ways of living.

Despite the impact of the pandemic on 2020 business plans and working environments, FIP persevered to deliver and launch the FIP Development Goals for our members and the profession worldwide, understanding the need to provide directions and goals in the coming years as we live with and (hopefully) move out of the pandemic.

In 2021, we ran a full programme to identify the priority goals for the decade ahead across our regions and members. In this event we recap the key outcomes and priorities across the world region which we captured in a new report.

Join us for launch the FIP Development Goals Report 2021 “Setting goals for the decade ahead” which provides a global status update on the goals one year on since their launch and serves as an anchor point that will facilitate the next decade’s roadmap aligned with the UN Agenda 2030.

We will also be launching a new ‘microsite’, a digital platform that serves as a web-based resource for the Development Goals. The microsite collates FIP’s work, publications, events and other outputs mapped to the goals by theme, alongside tools and resources for our members.

Join us in one of FIP’s first events of 2022, where we stand by our commitment now and in the future to support our members to transform pharmacy with clear action, in solidarity with all!

This event discusses how targeted switching of prescription only medicines to non-prescription medicines (Over The Counter medicines) can contribute to self-care of a nation’s population. Availability of diagnostics in the pharmacy and beyond can also make an impact on self-care.

Aim: To discuss which medicines are appropriate to switch from prescription-only to non-prescription (Over The Counter Medicines) and describe how diagnostics can support self-care.

Learning objectives:
1. Describe current approaches to switching medicines from prescription to non-prescription and how this supports self-care ;
2. Discuss which medicines should be available over the counter in the pharmacy;
3. Explain how diagnostics can support self-care.

Moderator:
- Jaime Acosta-Gómez, Community Pharmacist and pharmacy owner, Farmacia Acosta, Spain

Panelists:
- Natalie Gauld, Innovator in improving access to medicines Northern Regional Alliance, University of Auckland, New Zealand
- Andi Shirtcliffe, Clinical Chief Advisor for Pharmacy and Allied Health Ministry of Health New Zealand, New Zealand
- Anthony Serracino Inglott, Professor at the Department of Pharmacy Faculty of Medicine and Surgery, University of Malta, Malta

Summary

Pharmacy teams are increasingly supporting children and their carers with self-care. This webinar will focus particularly on appropriate management of choices of medicines and products to support children’s health, and the role of the pharmacist. A case study will be presented and the event will conclude with a panel discussion.

Aim: To identify how the community pharmacy team can support self-care of common health problems for children and their carers.

Learning objectives: 

1. Increase awareness of children’s health issues, how common they are, what impacts they have and how they can be managed;
2. Learn how to support carers and children with common health issues;
3. Discuss appropriate management in the choice of medicines and products.
4. Describe the role that pharmacist and their team can play in advising and educating carers and children so they can self-care.

Moderator:

• Sarah Dineen-Griffin, Lecturer in health services management and leadership, Charles Sturt University, Australia

Panellist:

• Hadi Dassouki, Community Pharmacist, Lebanon
• Jack Collins, Postdoctoral Research Associate, The University of Sydney School of Pharmacy, Australia
• Joanne Crook, Consultant Pharmacist Paediatrics, Kings College Hospital, UK

The FIP Development Goals Digital Programme “Setting goals for the decade ahead” is a comprehensive online event series providing coverage of the 21 goals over 21 events in 2021. Starting in March, the 21 digital events aim to provide description, direction and context for each specific goal, with a global plan for the decade ahead and how each nation, within each region can identify and prioritise which goals are the priorities and how the goals can support developments and transformation for them.

This programme is all about engaging the profession and supporting the profession to deliver in relevant and purposeful ways. By engaging our profession, members & colleagues everywhere with these relevant and applicable goals for the decade ahead, we can provide tools, monitoring and evaluation through data evidence, and identifying priorities across practice, science, and workforce & education.

Find out more about the FIP Development Goals here: www.fip.org/fip-development-goals

The Global Advanced development framework (GADF) was developed to support the professional development and recognition of the pharmacy workforce everywhere and the Global Competency Framework (GbCF) was developed by the FIP as a focused support structure for early career pharmacists.  This digital event seeks to create more awareness for the GADF and GbCF and to enable early career pharmacists and pharmaceutical scientists have a better understanding of their structure.

Competency framework- A complete collection of competencies that are thought to be essential to performance.

Competencies – Knowledge, skills, behaviors and attitudes that individuals accumulate, develops, and acquires through the education, training and work experience.

Learning objectives:

• Describe the purpose and applications of both the Global Advanced Development Framework (GADF) and the Global competency framework (GbCF);
• Summarize the domains and illustrative competencies from the GbCF for pharmaceutical services (scientific knowledge and management knowledge)
• Identify an individual learning plan based on their learning needs obtained from the self-assessment of GbCF;
• Discuss approach to building a professional practice portfolio.

Moderator:

• Ayodeji Matuluko, Remote Volunteer, FIP Commission on AMR, PhD Candidate, Glasgow Caledonian University, Nigeria

In October-2021, FIP-UNITWIN Regional Workshops brought FIP’s member academic institutions, professional organisations, key pharmacy stakeholders and guests across all regions together to co-create a roadmap to advance pharmacy and pharmaceutical sciences in their region through educational partnerships. At the FIP-UNITWIN Global Summit on pharmaceutical education, participants will.

Learning objectives:
1. Learn about their regions’ roadmap on advancing pharmacy and pharmaceutical sciences education;
2. Explore FIP’s global call to action on pharmaceutical education to support it across their regions and countries;
3. Discover country cases and next steps of the FIP-UNITWIN Centres for Excellence programme

Chairs:

• Catherine Duggan, FIP CEO
• Ralph J. Altiere, FIPEd Chair

Speakers:

• Dominique Jordan, FIP President
• Luis Lorenco, FIP Professional Secretary
• Giovanni Pauletti, FIP Scientific Secretary
• Pierre Moreau, FIP AIM Chair

Panellists:

• Anne Anderson Vice Chair, UK National Commission for UNESCO
• Toyin Tofade, President-Elect of the FIP Academic Pharmacy Section (AcPS) & FIP AIM Advisory Committee Member
• Silvana Nair Leite, FIP AIM Advisory Committee member
• Lilian Azzopardi, AIM Advisory Committee member
• Aukje Mantel-Teeuwisse,FIP Digital Health in Pharmacy Education Report Chair, FIP Technology Forum Member, FIP APS Executive Committee Member
• Beom-Jin Lee, AIM Advisory Committee member
• Rajani Shakya, AIM Advisory Committee member
• Mohamad Rahal, AIM Advisory Committee member
• Rula Darwish, Academic Pharmacy Section Exco
• Paul J. Gallagher, AIM Advisory Committee member
• Mwila Chiluba, AIM Advisory Committee member
• Yahya Choonara, AIM Advisory Committee member
• Arinola Joda, Asst. Secretary/Editor in Chief, APF

Facilitators:

• Nilhan Uzman, FIP Lead for education policy and implementation
• Ozge Ozer, FIP Educational Partnership Coordinator
• Alison Ubong Etukakpan, FIP Educational Partnership Coordinator

The FIP Development Goals Digital Programme “Setting goals for the decade ahead” is a comprehensive online event series providing coverage of the 21 goals over 21 events in 2021. Starting in March, the 21 digital events aim to provide description, direction and context for each specific goal, with a global plan for the decade ahead and how each nation, within each region can identify and prioritise which goals are the priorities and how the goals can support developments and transformation for them. The 20^th episode of the Programme focuses on FIP Development Goal 14: Medicines Expertise. The details of the Goal are available here: https://www.fip.org/fip-development-goal-14

The expected outcomes of the event are:

1. Describe the FIP Development Goals and explain the components of DG 14 (and its three elements: workforce & education, science and practice).
2. Showcase the FIP tools, evidence, and resources to support DG 14 implementation across the three elements.
3. Identify priorities across practice, science, and workforce & education within DG 14
4. Discuss the importance monitoring and evaluation through data evidence and engage participants with FIP indicators development project

Moderator:

• Dalia Bajis, FIP Lead for Provision and Partnership, Bahrain 

Panellist:

• Hala Fadda, Chair of FIP Pediatric Formulations Focus Group, Associate Professor, College of Pharmacy and Health Sciences Buter University, USA
• Sham Moodley, Pharmacist, FIP CPS Exco Member, Pharmaceutical Society of South Africa/Independent Community Pharmacy Assoc (ICPA), South Africa

Summary
There is variability across the globe in the provision of universal healthcare. Self-care is the ability to maintain and improve individual’s health, prevent or limit diagnosed illnesses, and address self-treatable conditions. Self care is not no care and it is not necessarily practised in isolation. It may involve support and advice from others, such as expert pharmacy teams.  This event discusses how self-care can contribute to Universal Health Coverage from the perspectives of providers of healthcare services and public and patients. 

Aim: To discuss the perspectives of providers of healthcare services and the people accessing them about how self-care can contribute to universal health coverage.

Learning objectives: 

• Explain the extent to which self-care is embedded in healthcare systems;
• Discuss cultural approaches to enabling self-care as part of UHC, such as healthy lifestyles;
• List healthcare systems and patients/public’s needs for enabling self-care;
• Discuss the contribution of localised self-care delivery to UHC

Moderator:

• Sham Moodley, Community Pharmacist, Member of the FIP Community Pharmacy Section, South Africa

Panellist:

• K Srinath Reddy, President, Public Health Foundation of India, India
  
• Jacqueline Bowman-Busato, Co-Founder, Belgian Private Foundation Pate Adiposité Adipositas Pacte, Belgium
• Dave Burrows, CEO and CTO, Damibu, UK

Traditionally, the distribution of medicines to consumers has been organized through heavily regulated networks of physical pharmacies. The strict regulation of market structure has been in place to ensure the safety, accessibility and affordability of medicines, but it has also limited competition in the pharmacy sector. Nowadays, the regulation of pharmacies differs between countries, and this has created different market conditions for online pharmacies to operate.

In some countries the online sales of medicines have grown considerably during the recent years as consumers have become more accustomed to e-commerce. More lately the Covid-19 pandemic has dramatically shaped the e-commerce landscape. Due to the pandemic, the demand for online services of pharmacies has increased significantly in many countries. It is also likely that this has changed preferences for some consumers permanently and demand should therefore remain at a higher level in the future.

Increased cooperation between countries in developing regulation of online pharmacies is needed, according to the report, “Online pharmacy operations and distribution of medicines”, which will be published by the International Pharmaceutical Federation (FIP) on December 8th, 2021.

Moderator:

• Lars-Åke Söderlund, FIP Vice President, Executive Advisor, Apoteket AB, Sweden, Sweden

Co-Moderator:

• Sarah Dineen-Griffin, Lecturer, Health Service Management, Charles Stuart University, Australia

Panellist:

• Catherine Duggan, FIP CEO, The Netherlands
• Manjiri Gharat, Principal, K. M. Kundnani Pharmacy Polytechnic, India
  
• Sari Westermarck, Community pharmacist, Finland
  
• Jacqueline Surugue, Immediate Past Vice President FIP, France
• Nadia Al Mazrouei, Assistant Professor, Sharjah University, United Arab Emirates (UAE) 
• Jorge Schlottke, Pharmacist, Centro Oncológico Integral de la Provincia de San Luis, Argentina
• John Jackson, President, Western Pacific Pharmaceutical Forum, Australia  
• Prosper Hiag, President, African Pharmaceutical Forum, Cameroon
• Jaime Acosta-Gómez, Community Pharmacist and pharmacy owner, Farmacia Acosta, Spain

Summary:

Gastrointestinal symptoms have an impact on the health and wellbeing of individuals that can be debilitating, however, the majority of people can be supported by the pharmacy team to self-care and effectively manage their symptoms.

Aim: 

To explore: lifestyle factors that can cause or worsen gastrointestinal complaints and the role of pharmacy team in supporting the majority of customers to self-care and effectively manage their symptoms.

Learning objectives: 

1. List common GI symptoms and their impact on people;
2. Identify and suggest approaches to addressing lifestyle factors causing GI symptoms.
3. Discuss the role of pharmacy team to support people with GI symptoms to self-care

Moderator:
- Manjiri Gharat, FIP Vice-President, India

Panellists:
- Ruth Rudling, Advanced Clinical Pharmacist for Specialty Medicines, Mid Yorkshire NHS Trust (MYHT), UK
- Anja St. Clair-Jones, Consultant Pharmacist Gastroenterology, University Hospitals Sussex, UK

At this event on World AIDS day, we will explore the different roles pharmacists can have in the prevention and screening of HIV infections, as well as in providing care and support to people living with HIV, namely through medication management. Other roles for pharmacists include HIV prevention through dispensing and providing support to preexposure prophylaxis (PrEP), HIV testing and harm reduction strategies for IV drugs users.

The World Health Organization estimates that around 38 million people live with HIV globally. Although there is still no cure for HIV, with the advancement of therapies and increasing access to effective HIV prevention, diagnosis, treatment and care, including for opportunistic infections, HIV infection has become a manageable chronic health condition, enabling people living with HIV to lead long and healthy lives.

Learning objectives:
1. Describe the burden and characteristics of HIV globally.
2. Understand the possibilities of involvement of pharmacists in the clinical care of people living with HIV.
3. Describe the role of pharmacists in PrEP-related services.

Moderator:
- Victoria Garcia Cardenas, FIP Pharmacy Practice Research SIG, Chair Senior Lecturer University of Technology Sydney, Australia / Spain

Panelists:
- Sham Moodley, FIP CPS Exco Member, Pharmacist Pharmaceutical Society of South Africa/Independent Community Pharmacy Assoc (ICPA), South Africa
- Nelli Barrière, Project Manager, HIV Programmes and Advocacy International AIDS Society, Switzerland
- Pilar Taberner Bonastre, Hospital pharmacist, Hospital Universitario Arnau de Vilanova, Lleida Spain
- Katrina F. Ortblad, Assistant Professor Fred Hutchinson Cancer Research Center, United States of America
- Tessa Oraro-Lawrence, Project Manager, HIV Programmes and Advocacy International AIDS Society, Switzerland

Para abogar por una implementación más amplia y armonizada de bioexenciones basadas en el sistema de clasificación biofarmacéutica (BCS) en los países de América Latina, la FIP está apoyando a los líderes regionales en la sensibilización sobre esta vía reguladora basada en la ciencia diseñada para acelerar la aprobación del mercado de productos farmacéuticos genéricos seguros y eficaces. La segunda parte de esta serie de seminarios web diseñados específicamente para la región de América Latina destaca ejemplos de vías de aprobación regulatoria de bioexenciones basadas en BCS que se implementan actualmente en países seleccionados de América Latina. Los expertos abordarán la base legislativa de las regulaciones de bioexenciones y discutirán las oportunidades de armonización dentro de la región.

Este webinar tiene los objetivos:

• Diferenciar entre la bioequivalencia in vivo y las estrategias reguladoras de bioexención basadas en BCS para la aprobación de medicamentos genéricos.
• Comprender las implicaciones para la salud pública de la vía reguladora de la bioexención basada en BCS.
• Delinear oportunidades y desafíos para la implementación de un proceso armonizado de aprobación regulatoria de bioexenciones dentro de la región de América Latina.
• Delinear las contribuciones de solubilidad, permeabilidad y disolución para aplicaciones de bioexención basadas en BCS.

Moderadora:
-Talita Ferreira, Coordinadora de Proyectos de bioexención en Latinoamérica FIP

Panelistas:
-Alfredo García Arieta, Jefe del Servicio de Farmacocinética y Medicamentos Genéricos AEMPS
-Andrés Figueroa Campos, Gerente SD Registro Sanitario de Productos Farmacéuticos Bioequivalentes
ANAMED ISPch–Agencia Nacional de Vigilancia Sanitaria de Chile
-Jorge Iliou, Dirección NVVS de Paraguay
-Alexis Aceituno,Jefe SD Registro Sanitario de Productos Farmacéuticos Bioequivalentes ANAMED ISPch–ANVSChile
-Miguel Angel Cabrera Prof. Asociado Central University of Las Villas

The global session entitled  ‘Accelerating AMR Action Through Antimicrobial Stewardship:  Are pharmacists the protagonists in the fight against antibiotic resistance?’ takes a debate format with 2 teams of three, protagonists and antagonists, speaking to a case study or personal experience to highlight good (protagonist) or bad (antagonist) practice that reflects the reality of the challenges faced by pharmacy in tackling AMR, with a particular focus on low to middle income countries

Moderators:
- Sabiha Essack
- Manjiri Gharat

Welcome and Objectives:
- Introducing FIP AMR Commission and goals of GRIP partnership; overview of 2020 -2021 roadmap progress
Panel Discussion:
- ‘Are pharmacists the protagonists in the fight against antibiotic resistance?’
Using case studies to highlight best practice, as well as bad practice, to reflect the reality of the challenges faced by pharmacy in tackling AMR, with a particular focus in low to middle income countries

Regional Highlights:
- Highlights of the regional ideas that delivered most change/progress towards the AMR roadmap developed in our FIP Virtual 2020 events

Next steps and close:
- Next steps and role of the AMR Commission; renewed commitment to AMR going forward

In 2020, Reckitt and the Global Respiratory Infection Partnership (GRIP) partnered with FIP to host a series of events combining efforts with the ambition of “Driving AMR action in a new decade”. One global event and six regional workshops were held, with over 4,000 participants engaging in collaborative efforts to identify and implement region-specific initiatives to mitigate AMR. The success of this partnership culminated in the FIP Regional AMR Roadmaps which identified regional initiatives to drive behaviour change and aid in the global fight against AMR.

This year GRIP, FIP and Reckitt continue to share this global commitment as we partner to bring you a series of events aimed at further driving a collaborative approach to AMR mitigation for pharmacy. Co-chaired by regional representatives from FIP and GRIP, we will aim to showcase the progress in the AMR Roadmap made in the South East Asian Region over the past 12 months.

Moderators:
- Manjiri Gharat
- Wirat Tongord

Welcome and Objectives:
- Introducing regional leads and recap of ambitions of the Pharmacy AMR Roadmap